



HHS Public Access

Author manuscript

ACS Appl Bio Mater. Author manuscript; available in PMC 2022 April 19.

Published in final edited form as:

ACS Appl Bio Mater. 2022 January 17; 5(1): 20–39. doi:10.1021/acsabm.1c00979.

Tissue Engineered Neurovascularization Strategies for Craniofacial Tissue Regeneration

Yiming Li,

Department of Biomedical Engineering, University of Rochester, Rochester, New York 14627, United States; Department of Orthopaedics and Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, United States

David Fraser,

Department of Orthopaedics and Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, United States; Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, New York 14620, United States; Translational Biomedical Sciences Program, University of Rochester Medical Center, Rochester, New York 14642, United States

Jared Mereness,

Department of Biomedical Engineering, University of Rochester, Rochester, New York 14627, United States; Department of Orthopaedics and Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, United States; Department of Environmental Medicine, University of Rochester Medical Center, Rochester, New York 14642, United States

Amy Van Hove,

Department of Biomedical Engineering, University of Rochester, Rochester, New York 14627, United States; Department of Orthopaedics and Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, United States

Sayantani Basu,

Department of Biomedical Engineering, University of Rochester, Rochester, New York 14627, United States; Department of Orthopaedics and Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, United States

Maureen Newman,

Department of Biomedical Engineering, University of Rochester, Rochester, New York 14627, United States; Department of Orthopaedics and Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, United States

Corresponding Author Danielle S. W. Benoit – Department of Biomedical Engineering, University of Rochester, Rochester, New York 14627, United States; Department of Orthopaedics and Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, United States; Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, New York 14620, United States; Translational Biomedical Sciences Program, Department of Environmental Medicine, and Department of Biomedical Genetics and Center for Oral Biology, University of Rochester Medical Center, Rochester, New York 14642, United States; Materials Science Program and Department of Chemical Engineering, University of Rochester, Rochester, New York 14627, United States; benoit@bme.rochester.edu.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The authors declare no competing financial interest.


Danielle S. W. Benoit

Department of Biomedical Engineering, University of Rochester, Rochester, New York 14627, United States; Department of Orthopaedics and Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, United States; Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, New York 14620, United States; Translational Biomedical Sciences Program, Department of Environmental Medicine, and Department of Biomedical Genetics and Center for Oral Biology, University of Rochester Medical Center, Rochester, New York 14642, United States; Materials Science Program and Department of Chemical Engineering, University of Rochester, Rochester, New York 14627, United States

Abstract

Craniofacial tissue injuries, diseases, and defects, including those within bone, dental, and periodontal tissues and salivary glands, impact an estimated 1 billion patients globally. Craniofacial tissue dysfunction significantly reduces quality of life, and successful repair of damaged tissues remains a significant challenge. Blood vessels and nerves are colocalized within craniofacial tissues and act synergistically during tissue regeneration. Therefore, the success of craniofacial regenerative approaches is predicated on successful recruitment, regeneration, or integration of both vascularization and innervation. Tissue engineering strategies have been widely used to encourage vascularization and, more recently, to improve innervation through host tissue recruitment or prevascularization/innervation of engineered tissues. However, current scaffold designs and cell or growth factor delivery approaches often fail to synergistically coordinate both vascularization and innervation to orchestrate successful tissue regeneration. Additionally, tissue engineering approaches are typically investigated separately for vascularization and innervation. Since both tissues act in concert to improve craniofacial tissue regeneration outcomes, a revised approach for development of engineered materials is required. This review aims to provide an overview of neurovascularization in craniofacial tissues and strategies to target either process thus far. Finally, key design principles are described for engineering approaches that will support both vascularization and innervation for successful craniofacial tissue regeneration.

Graphical Abstract



Keywords

engineered tissue regeneration; craniofacial tissue; neurovascularization; biomaterial design; growth factor; cell therapy; hydrogel

1. INTRODUCTION

The craniofacial complex is composed of various tissues including cranial, maxillary, and mandibular bones, dental and periodontal tissues, and salivary glands.^{1,2} These structures provide critical functions including protection of the brain and oral cavity, mastication, defense against bacteria, and assisting in digestion.³ Destruction or loss of craniofacial tissues has many underlying causes. Craniofacial bone defects can occur following injury, tumor resection, or as a result of dysfunctional development.⁴ Dental pulp and periodontal tissues can be damaged by dental caries and periodontitis.^{5,6} Xerostomia, or chronic dry mouth, occurs due to bystander damage of salivary glands during radiation treatments or destruction due to Sjögren's Syndrome.⁷⁻⁹ Craniofacial tissue dysfunction significantly reduces quality of life, and successful repair of damaged tissues remains a significant challenge.¹⁰ The current lack of approaches to restore function to cranial and oral tissues demands innovative tissue engineering and regenerative medicine approaches.

While the field of tissue engineering has made remarkable progress, vascularization remains a significant and long-standing hurdle for engineered scaffolds including those for craniofacial tissues.¹¹ Additionally, craniofacial tissues are highly innervated. Nerves are found in close proximity to blood vessels and are increasingly recognized as critical coregulators of tissue regeneration.¹²⁻¹⁴ While vascularization has been targeted with tissue engineering approaches in cranial and alveolar bone defect healing^{15,16} and dental tissue regeneration,^{17,18} innervation has received much less attention, and coordinated innervation and vascularization has not been directly investigated for craniofacial tissue regeneration.

Here, we review the biological processes underpinning both vascularization and innervation and their crosstalk in craniofacial tissues. We then describe methods employed to date to promote angiogenesis and innervation, either directly in the context of craniofacial tissue regeneration or in general for tissue engineering. Finally, we discuss the microenvironmental cues that may pave the way for successful neurovascular tissue engineering strategies for craniofacial tissues.

2. INNERVATION AND ANGIOGENESIS IN CRANIOFACIAL TISSUE REGENERATION

2.1. Innervation and Angiogenesis after Injury.

Peripheral nerves can regenerate after injury. Over the first 24 h following axotomy, nerve stumps retract due to dissolution of the cell membranes adjacent to the injury, and macrophages are recruited to the injury site. Distal axons undergo Wallerian degeneration (Figure 1), which is the coordinated removal of the axon and tissue debris by Schwann cells and macrophages. Schwann cells (SCs) proliferate in response to myelin debris and macrophage-secreted cytokines, then align in tubes known as Bungner bands, which express chemotactic cues including nerve growth factor (NGF) to attract and guide proximal axon reinnervation, resulting in functional recovery of their tissue targets (Figure 1).¹⁹⁻²² Schwann cell proliferation can also be stimulated by target organ-derived trophic factors such as glial derived growth factor (GDGF) and brain-derived neurotrophic factor (BDNF).²²

Angiogenesis occurs in response to tissue hypoxia, or low oxygen tension, following injury-mediated disruption of vascularization. A representation of this process is shown in Figure 2, which includes a summary of key cells and growth factors. First, cells in ischemic tissue increase production of hypoxia inducible factor 1 α (HIF-1 α), which induces production of vascular endothelial growth factor (VEGF) that diffuses into the nearby tissue. These factors signal to pericytes and endothelial cells (ECs) of nearby vasculature, causing detachment of pericytes and sprouting of endothelial tip cells toward the signal gradient. Tip cells then migrate in the direction of the gradient, degrading the local extracellular matrix to enable stalk cells to proliferate and form vessels. Stalk cells align in tube-like luminal structures, forming an immature vascular network. Pericytes are then recruited to the newly formed vasculature, stabilizing the immature vessels, and participating in vessel remodeling.

Vascularization and innervation share many developmental and anatomical similarities including reciprocal signals that influence their development. To establish proper connections within the vasculature and nervous system, chemotaxis of axons or blood vessels is orchestrated by similar structures: the growth cone in axons or tip cells in vessels.^{19,23,24} Endothelial and nerve cells can both secrete angiogenic and neurogenic factors during vessels and nerve regeneration. Recent studies suggest that endothelial cell paracrine factors provide critical cues for recruiting and controlling innervation.^{25,26} Specifically, endothelial cells secrete artemin and neurotrophin 3 that recruit axons to track alongside vessels.^{27,28} In turn, nerves secrete VEGF in a spatiotemporally controlled manner to coordinate vessel growth.²⁹ Further, stimulation of neuronal activity can also trigger angiogenesis.^{30,31}

2.2. Coupled Innervation and Angiogenesis in Craniofacial Tissue Regeneration.

2.2.1. Craniofacial Tissues Are Vascularized and Innervated.—Craniofacial tissues, including cranial and mandibular bone, dental tissue, and salivary glands, are highly vascularized and innervated with blood vessels and nerves in close juxtaposition (Figure 3). For example, the calvarial periosteum and diploë, the cancellous bone separating the inner and outer layers of the cortical bone of the skull, are innervated by peripheral nerve fibers, including both sensory and sympathetic fibers.^{33,34} Some small sensory nerve fibers depart blood vessels and wind through the periosteum, while the main sensory nerves follow blood vessels, terminating in the lining layer of periosteum or continuing along vessels into bone via Volkmann's canals.³⁵ Sympathetic fibers often wrap around blood vessels penetrating from the periosteum into the diploë.³⁵

Dental vessels and nerves course from the inferior alveolar nerve and vessels in the mandible (Figure 3Bi) and from branches of the maxillary artery and nerve in the maxilla, entering the dental pulp primarily through the apical foramen at the tooth root end (apex) (Figure 3Bii). Arterioles in the central pulp region supply a peripheral capillary network adjacent to dentin walls.³⁶ Autonomic nerve fibers are found primarily in association with the vasculature, while sensory nerve fibers form a network around the pulp periphery and can enter dentin tubules in close relationship to odontoblasts.³⁷ Additionally, the periodontal ligament (PDL) surrounding the cementum lining the tooth root and connecting alveolar bone, is vascularized and innervated.³⁸ Conversely, cementum is avascular and contains no nerves.³⁹ Progenitor and stem cell populations in both dental pulp and PDL are closely associated with the neurovasculature^{40,41} and sensory denervation can inhibit stem cell proliferation and differentiation.⁴²

Vessels and nerves are also colocalized within the salivary gland (Figure 3C). Vessels enter the salivary gland from the external carotid artery and closely associate with the duct network of the salivary tissue together with nerves⁴³ (Figure 3C). These vessels form dense capillary networks around the terminal ends of the secretory acinar units, which are also enveloped by nerves.⁴⁴ Salivary gland innervation, similar to the pulp and PDL, is required for gland function and repair, controlling salivary secretion, and possibly maintaining salivary epithelial progenitor cell populations.⁴⁵⁻⁴⁷ Thus, vessels and nerves colocalize and play important roles in tissue homeostasis in craniofacial tissues.

2.2.2. Innervation and Angiogenesis Coordinate Craniofacial Tissue

Regeneration.—Blood vessels and nerves synergistically coordinate tissue regeneration.⁴⁸⁻⁵⁴ In bone, healing is initiated by hematoma and inflammation, which leads to cytokine release from inflammatory cells, followed by increased blood flow and cell migration to the injured site.⁵⁵ Mesenchymal stem cells (MSCs) and osteoprogenitors migrate to the defect area and differentiate into osteoblasts to form the ossification center.⁵⁶ Within the hypoxic wound, osteoblasts synthesize and secrete VEGF in response to elevated levels of HIF-1 α , which then stimulates angiogenesis. Blood vessels sprouting from preexisting vessels to the defect center can be observed within the first week after injury in mouse cranial defect models^{57,58} (Figure 4A). Inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor (TNF)- α , directly induce NGF expression and downstream nuclear factor kappa B (NF- κ B) signaling in calvarial osteoblasts to stimulate nerve recruitment.⁵⁹ Reinnervation, which is associated with blood vessels, can be observed as early as 3 days postinjury in mouse cranial defects (Figure 4B).⁶⁰ Nerves play diverse roles during osteogenesis, regulating the canonical/ β -catenin Wnt signaling pathway and expression of Connexin 43 (Cx43) and N-cadherin in MSCs⁶¹ as well as secreting vasculogenic neuropeptides, including neuropeptide Y (NPY), calcitonin gene-related peptide (CGRP), and substance P (SP), to stimulate angiogenesis.^{62,63} Increased angiogenesis recruits additional osteoprogenitors to the repair site, along with nutrients, oxygen, and minerals necessary for mineralization. Concomitantly, endothelial cells produce osteogenic factors, such as transforming growth factor beta (TGF- β) and bone morphogenetic protein-2 (BMP2), to further promote osteogenic differentiation and bone mineralization.^{64,65}

Dental and periodontal tissue repair also requires the orchestrated effort of vessels and nerves. Dental pulp has an inherent, albeit limited, regenerative capacity, which requires mesenchymal cell infiltration, innervation, and angiogenesis from adjacent healthy tissues into the pulp space.⁶⁶ Dental pulp injuries result in hypoxia where pulp cells respond by secreting HIF-1 α to drive downstream expression of VEGF, platelet derived growth factor (PDGF), fibroblast growth factor (FGF)-2, and angiopoietins to promote angiogenesis.⁶⁷ Additionally, pulpal nerves respond to injury with sympathetic nerves releasing NPY and norepinephrine leading to vasoconstriction, while sensory neurons release neuropeptides such as SP and CGRP, which promote vasodilation and recruit immune cells.⁶⁸ Neuropeptides induce nerve sprouting adjacent to the pulpal injury, with further neuropeptides released from these sprouting fibers leading to additional immune cell recruitment, vasodilation, and continued healing.³⁷ The pulp chamber of mature teeth presents a particularly challenging space for tissue regeneration: new nerves and vessels must sprout from existing vessels and nerve trunks up to 15 mm away and enter through a narrow apical foramen 0.2 to 0.4 mm in diameter.^{69,70}

Similar to bone, initial healing of the periodontium is characterized by the release of cytokines such as PDGF, TGF- β , VEGF, and bFGF from platelets and infiltrating immune cells, which then stimulates angiogenesis and recruitment of host cells from adjacent periodontal tissues.⁷¹ Recombinant PDGF-BB and autologous platelet-derived factors promote periodontal wound healing and tissue regeneration^{72,73} and likely stimulate

angiogenesis during this process. PDL nerves produce low levels of neuropeptides during tissue homeostasis⁷⁴ yet retain the ability to remodel and regenerate in response to external stimuli.^{75,76} The PDL responds to orthodontic force with nerve fiber sprouting, increased production of both sensory (SP, CGRP) and sympathetic (NPY, tyrosine hydroxylase) neuropeptides, and increased capillary density together with transient local bone resorption.⁷⁷⁻⁷⁹ PDL nerves also express the high affinity neurotrophin receptor tropomyosin receptor kinase B (TrkB)⁸⁰ and high levels of NGF receptor p75-NGFR and growth associated protein-43 (GAP-43), factors associated with neuroplasticity.⁸¹ Neurotrophins and neurotrophin receptors are also expressed by periodontal ligament cells,⁸² and cells within healing periodontal defects, including infiltrating endothelial cells, express TrkB.⁸³ The epithelial rests of Malassez (ERM) and associated nerves may also play a key role in periodontal wound healing,⁸⁴ as sensory denervation results in a reduction in the size and number of ERM⁸⁵ and ankylosis of tooth to bone.⁸⁶

There are few studies examining the role of vessels and nerves in salivary gland regeneration, despite studies indicating their importance in secretory acinar cells regeneration. During gland development, signaling from CD31⁺ endothelial cells via vascular endothelial growth factor receptor 2 (VEGFR2) is required for proper tissue patterning by helping maintain Kit⁺ progenitor cells and promoting branching morphogenesis.⁴³ Additionally, secretion of vasoactive intestinal peptide (VIP) by innervating ganglia is necessary for duct growth and lumen formation during branching morphogenesis,⁸⁷ and parasympathetic innervation promotes SRY-Box transcription factor 2 (SOX2) expression by progenitor cells in the developing gland.⁸⁸ Expression of SOX2 is essential for the production of secretory acinar cells, but not duct cells, and is maintained in a subset of cells in adult gland,⁸⁹ which has been shown to replace acinar cells under homeostatic conditions.^{89,90}

2.3. Failures in Angiogenesis or Innervation Result in Deficient Craniofacial Tissue Regeneration.

Innervation and vascularization are both necessary for successful craniofacial tissue regeneration. For example, a significant decrease in ossification of calvaria has been observed in conditional VEGF knockout mice or those with impaired FGF signaling due to inadequate angiogenesis.^{91,92} Inhibition of VEGFR2 or depletion of endothelial cells embryonically leads to loss of secretory acinar cells.⁴³ Additionally, deletion of NGF leads to dramatic reductions in nerve sprouts, angiogenesis, and delayed regeneration of cranial defects.⁶⁰ Sensory denervation also leads to alterations in osteoclasts, which subsequently delay cranial bone defect healing,⁹³ bone formation during mandibular repair,⁹⁴ orthodontic tooth movement,⁹⁵ and mineralization of new bone within the periodontium.^{96,97} Denervation also leads to decreases in pulp cell proliferation⁹⁸ and increased susceptibility to pulpal necrosis after bacterial exposure.⁹⁹ Sympathectomy or treatment with sympathetic antagonists during tooth movement suppresses osteoclast activity but not bone formation⁷⁹ and also leads to periodontal bone loss via increased production of inflammatory cytokines in the periodontal tissues and subsequent osteoclast activity.¹⁰⁰ Moreover, denervation⁹⁰ or disruption of innervation prevents salivary gland regeneration in

ductal ligation models, despite progenitor cell maintenance,¹⁰¹⁻¹⁰³ suggesting a critical role for innervation.

Altogether, these studies emphasize the necessity of both angiogenesis and innervation for successful craniofacial tissue regeneration and point to the possibility of superior integration with the host tissue and minimum long-term complications for regenerative approaches that target both processes.

3. CURRENT CRANIOFACIAL TISSUE REGENERATIVE APPROACHES THAT TARGET INNERVATION OR VASCULARIZATION

3.1. Growth Factor Delivery.

3.1.1. Growth Factor Delivery to Stimulate Reinnervation.—The growing appreciation of the role of reinnervation in tissue regeneration has resulted in several studies exploiting delivery of neuronal growth factors and neuropeptides to promote craniofacial tissue regeneration. These growth factors include NGF, BDNF, SP, galanin, and neurturin (NTRN). For example, NGF has been incorporated into bone scaffolds to treat rat cranial defects, showing an increase in innervation but limited new bone formation.^{104,105} NGF delivery via alginate hydrogels has also been used to increase bone and cementum formation in periodontal defects.¹⁰⁶ Local injection of SP promoted bone formation during mandibular distraction osteogenesis in rats,⁹⁴ and BDNF delivery from collagen sponges^{107,108} or using hyaluronic acid hydrogels^{83,109-111} led to increased bone, PDL, and cementum formation compared to scaffold controls. Galanin-loaded collagen sponges promoted bone formation in inflammatory periodontal defects.¹¹² Overexpression of NTRN prior to irradiation was protective of salivary gland innervation and function,¹¹³ and laminin matrices with entrapped NTRN promoted neurite outgrowth from isolated parasympathetic submandibular ganglia (PSG), reduced neuronal apoptosis, and increased the number of end buds, progenitor cells, and innervation in mouse submandibular glands exposed to irradiation.¹⁰¹ Additionally, salivary gland cell sphere cultures combined with mesenchyme and PSG in matrices containing NRTN became innervated and underwent branching similar to development.¹¹⁴

3.1.2. Growth Factor Delivery to Promote Vascularization.—A common approach to achieve vascularization is delivery of angiogenic proteins including VEGF, FGFs, and PDGF.^{115,116} For example, VEGF,^{117,118} FGF-2,¹⁵ and PDGF¹⁶ delivery enhanced local angiogenesis and osteogenesis in some cranial defect models. However, another study showed vascularization and new bone regeneration after scaffold-mediated VEGF led to similar results as a control group, with only 26% of the defect covered by newly formed bone 12 weeks after injury,¹¹⁷ suggesting that VEGF-mediated vascularization alone is insufficient to support a robust regenerative response. Previous studies have also demonstrated the ability of VEGF and FGF-2 to promote dental pulp angiogenesis.¹¹⁹⁻¹²¹ The delivery of VEGF (together with dental pulp stem cells (DPSCs)) from heparin-conjugated gelatin microspheres in tooth roots also supported formation of vascularized pulp tissue.¹²²

3.1.3. Delivery of Multiple Growth Factors to Stimulate Innervation or Vascularization.—Combinatorial approaches of neurogenic and angiogenic and, in some cases, osteogenic growth factors have also shown promise. Recent studies suggest delivery of multiple pro-angiogenic proteins can result in therapeutically relevant and long-lasting vascularization, which is necessary for regeneration.¹²³⁻¹²⁶ For example, combined delivery of VEGF and BMP-2 promoted osteogenesis and angiogenesis in cranial defects.^{127,128} Additionally, the combined delivery of VEGF or FGF2 with NGF and BMP-7 to dental pulp chambers led to angiogenesis, recellularization, and new dentin formation.¹²⁹ NGF has also been delivered by alginate hydrogels together with BMP-2, resulting in synergistic effects on periodontal bone and cementum formation.¹⁰⁶ Additionally, fibrin hydrogel-mediated delivery of pro-angiogenic VEGF and FGF9, which recruits vessel stabilizing mural cells and maintains neuronal cell viability and function,^{130,131} enhanced salivary gland regeneration and saliva production in a gland injury model.¹³²

3.1.4. Peptides as Alternatives to Growth Factors for Vascularization.—Protein delivery approaches can suffer from poor long-term outcomes due to insufficient protein stability and rapid clearance¹³³⁻¹³⁵ as well as challenges associated with precise control over growth factor release kinetics.^{11,136} Therefore, therapeutic peptides have recently gained interest as an alternative to proteins. Their smaller size¹³⁷ gives them more versatile synthetic schemes than proteins and allows peptides to be delivered at higher concentrations to target tissues when applied locally. Additionally, peptides often do not require complex tertiary structures for bioactivity, increasing *in vivo* stability.¹³⁸ For example, VIP-conjugated hydrogels have been reported to enhance cranial bone defect repair,¹³⁹ where VIP not only stimulated tube formation and VEGF expression but also promoted bone marrow stem cell (BMSC) differentiation by activating the Wnt- β -catenin signaling pathway. Self-assembling peptide hydrogels for pulpal regeneration were synthesized to contain a pro-angiogenic peptide sequence, QK, derived from VEGF or dentonin, an odontogenic peptide.¹⁴⁰ Roots treated with hydrogels without bioactive peptides or containing only the odontogenic peptide formed disorganized connective tissue, while hydrogels containing QK showed formation of pulpal tissues with new odontoblast-like cells, blood vessels, and nerves. A recent study delivered dimethylxalylglycine, a glycine derivative that inhibits prolyl hydroxylase to activate HIF-1 α , via nanosilicates entrapped within poly(L-lactide-co-glycolide) (PLGA) scaffolds, to promote angiogenesis and tissue regeneration in periodontal defects.¹⁴¹

3.2. Implantation of Prevascularized or Innervated Scaffolds.

Several techniques have been employed to develop prevascularized constructs.¹⁴²⁻¹⁵⁰ These approaches exploit both fully differentiated as well as progenitor cell types. For example, DPSCs were precultured in endothelial differentiation media to form Von Willebrand factor (vWF) and CD31-positive reticular structures, which supported formation of vascularized pulp tissue and differentiated odontoblasts.¹⁵¹ Additionally, a preformed endothelial network was incorporated into bone scaffolds to promote vascularization and osteogenesis in a rat cranial defect model.¹⁵² However, only 25% of increased bone volume was observed despite increased blood vessel volume after 8 weeks, a result that may be due to no or poor innervation.¹⁵² Prevascularization strategies face challenges to ensure stable tissue formation

and anastomosis within host tissues. EC-only derived vasculature is commonly unstable, lasting only a few days *in vitro*. Cocultures of ECs and vessel-stabilizing MSCs or other pericyte-like cells can extend vascular network stability for >60 days *in vitro* in engineered extracellular matrices and facilitate tissue integration *in vivo*.^{153,154} As an example, spheroids composed of BMSCs and human umbilical vein endothelial cells (HUVECs) were encapsulated in fibrin scaffolds to form vascular networks prior to implanting the scaffolds in rat cranial defects.¹⁵⁵ The preformed vascular networks survived and anastomosed with host tissue within 1 week of implantation but ultimately did not significantly enhance bone regeneration compared to controls.¹⁵⁵

Innervated tissue engineering approaches have been utilized in a few applications to recapitulate Wallerian degeneration to guide nerve integration and promote healing. Though not specific to craniofacial tissues, preinnervated tissue engineered muscle was formed using a coculture of myocytes and motor neurons on aligned nanofibrous scaffolds. The presence of neurons enhanced the differentiation and maturation of skeletal myocytes *in vitro* and significantly increased satellite cell migration, microvessel formation and revascularization, and neuromuscular junction density *in vivo*.¹⁵⁶ Though not a direct preinnervation approach, incorporating sensory nerve tracts in bioceramic-based scaffolds has been reported to enhance both neurogenesis and bone formation.¹⁵⁷

4. DEVELOPMENT OF TISSUE ENGINEERING APPROACHES FOR NEUROVASCULARIZATION

Tissue engineering approaches that address both innervation and vascularization hold great potential to promote craniofacial tissue regeneration¹⁵⁸ as opposed to targeting only vascularization¹⁵⁹⁻¹⁶¹ or innervation.¹⁶²⁻¹⁶⁵ These approaches can be adopted from traditional tissue engineering approaches and include cells,^{166,167} synthetic¹⁶⁸⁻¹⁷⁰ and natural^{166,171,172} scaffolds, growth factors,^{173,174} and combinations therein,^{127,175} which are detailed in the following sections.

4.1. Cells for Neurovascular Tissue Regeneration.

A variety of cell types have been used to promote neurovascularization for craniofacial tissue regeneration. These include stem cells, such as MSCs, DPSCs, and induced pluripotent stem cells (iPSCs), SCs, and ECs. Cells participate in regeneration via many mechanisms, including tissue-specific matrix deposition as well as secretion of growth factors, to facilitate tissue recruitment and neurovascular tissue development. For example, SCs can direct axon migration and regulate their proliferation via neurotrophic factor expression (Figure 4);¹⁷⁶ ECs can mediate angiogenesis and osteogenesis by producing paracrine factors¹⁷⁷ and proliferation, migration, and assembly into tubular structures¹⁷⁸ (Figure 2). Therefore, SCs^{166,179-181} and ECs^{167,182-184} have been incorporated in tissue engineering constructs to promote peripheral nerve regeneration and angiogenesis during bone repair, respectively. Other systems have utilized cocultured stem cells/SCs^{175,185,186} and stem cells/ECs.¹⁸⁷⁻¹⁹² MSCs have been shown to differentiate into osteoprogenitors as well as Schwann-like cells^{193,194} and may give rise to neurons¹⁸⁶ and enhance axonal regeneration.¹⁸⁵ Though controversial, some studies have also reported that MSCs can

differentiate into endothelial cells.^{195,196} Additionally, MSCs cocultured with ECs have been reported to act as pericytes during angiogenesis *in vitro*¹⁹⁷ and *in vivo*,¹⁹⁸ where MSCs localize along the endothelial tubes and encourage vascular network formation by secreting angiogenic growth factors such as VEGF and bFGF.^{199,200} Human DPSCs have been reported to enhance HUVEC migration and VEGF secretion as well as promote ECM deposition and mineralization during dental pulp regeneration.²⁰¹ Hence, the integration of cocultured SCs/ECs or SCs/ECs/stem cells into cellular approaches may improve neurovascularization for craniofacial tissue regeneration. However, the clinical application of many cell types has been limited by source of human cells and lack of *in vitro* expansion capacity.^{202,203} In this regard, iPSCs, which can be reproducibly differentiated into myriad cell types including ECs²⁰⁴ and neurons,²⁰⁵ are promising alternatives. Previous studies have demonstrated that iPSC-derived ECs significantly increase vascularization *in vivo*.^{206,207} Moreover, iPSC-derived neural crest stem cells (NCSCs) and NCSC-SCs have been reported to encourage nerve regeneration *in vivo*, where they interacted with host axons and produce neurogenic factors (NGF and BDNF).²⁰⁸ Though the application of iPSCs for craniofacial neurovascularization has not been reported, its potential has been discussed.²⁰⁹⁻²¹¹

4.2. Design of Biomaterials for Neurovascularization.

Biomaterials used in craniofacial tissue engineering must be designed to support peripheral nerves and vessels. Biomaterial design, therefore, must take into account many complex design requirements including biophysical and biochemical cues.^{212,213} Moreover, biomaterials should be biodegradable and may also need to provide control over release of therapeutic factors to encourage cell migration, axonal growth, and vessel infiltration.²¹⁴⁻²¹⁶ In the following sections, we summarize various biomaterials classes and design criteria enabled by new chemistries and fabrication techniques for the regeneration of neurovascularized tissues.

4.2.1. Biomaterial Classes for Neurovascularization.—Because of excellent biocompatibility, natural polymers, such as collagen,^{171,217-219} chitosan,^{172,220-222} and silk,¹⁶⁶ have been utilized to promote neurovascularization *in vivo*. For example, chitosan has been reported to support ~50% regeneration and tissue reinnervation in a rat critical nerve gap model.²²² Neovascularization has also been observed in chitosan scaffolds after 12-weeks of implantation *in vivo*.²²³ Additionally, cell/growth factor-loaded collagen-based scaffolds have been reported to promote nerve regeneration²²⁴ and vascularization²²⁵ *in vivo*. However, the use of natural polymers is hindered by their complex chemical structures, uncontrolled degradation, and thermal sensitivity.²²⁶ Alternatively, synthetic polymers can be tailored to match biophysical and biochemical properties demanded by vascularization and innervation and enable delivery of cells and bioactive factors. Previous studies have demonstrated that polymers such as poly(glycolic acid) (PGA),^{227,228} poly(lactic acid) (PLA),²²⁹⁻²³¹ PLGA,²³²⁻²³⁵ and poly(caprolactone) (PCL),²³⁶⁻²³⁸ combined with cells¹⁶⁸ and growth factors,¹⁶⁹ can encourage peripheral nerve regeneration *in vivo*. However, application of synthetic polymers in nerve repair still remains a clinical challenge.^{239,240} Even biomaterials approved by the FDA for specific applications, such as NeuraGen,²⁴¹ Neuromaix,²⁴² and NEUROLAC,²⁴³ provide only limited repair for nerve defects longer

than 3 cm. Synthetic polymers, such as PGA,^{244,245} PLA, and PLGA,^{161,246,247} have also been developed as delivery vehicles of angiogenic growth factors to promote neovascularization *in vivo*. Nevertheless, the effects of these scaffolds on angiogenesis can be hindered because release profiles of the incorporated growth factors are difficult to control and often do not match what is required to achieve regeneration.²⁴⁸

Various hydrogel biomaterials have also been explored in neural and vascular tissue engineering. Hydrogels have great utility in tissue engineering in general due to high water content, ability to be tailored via functionalization by exogenous biochemical cues, incorporation of cross-linkers degradable by various modes and rates, and incorporation and control over growth factor release.^{32,249-254} Poly(ethylene glycol) (PEG)²⁵⁵ and gelatin-based hydrogels²⁵⁶ promoted the regeneration of rat sciatic nerves, as evidenced by increased axon number and diameter. Gelatin hydrogels have been used in multiple studies to promote angiogenesis during bone repair through the delivery of various growth factors.^{248,257-259} PEG-based hydrogels have also been used to deliver growth factors¹⁵⁹ and cells^{260,261} to improve angiogenesis during bone regeneration *in vivo*. Despite promise, hydrogel-based materials have not yet been effectively used to promote both angiogenesis and innervation in the regeneration of craniofacial tissues.^{262,263}

4.2.2. Biomaterial Physical Cues for Neurovascularization.—Biomaterials designed for neurovascularization should provide a 3D microenvironment with proper biophysical cues, including pore size/porosity, stiffness, and degradation dynamics, to support endothelial and nerve cell growth and migration. Previous studies have demonstrated that a pore size of 35–100 μm with at least 50% porosity is optimal for blood vessel formation.^{264,265} Cells may rapidly migrate from scaffolds with pore sizes too large, and smaller pore size can hinder oxygen and nutrition diffusion and cell migration, resulting in unstable vessels.²⁶⁶ The optimal pore size for innervation was reported to be in the ~5–30 μm range with >80% porosity to enable nutrient and waste exchange and neuron infiltration.²⁶⁷⁻²⁶⁹

The morphology, organization, and function of endothelial²⁷⁰ and nerve tissues²⁷¹ have also been reported to be influenced by substrate stiffness. In 3D culture systems, which have greater relevance for tissue engineering than 2D studies, more robust neurite outgrowth was observed in softer matrices (0.5 kPa) than stiffer matrices (1.4 kPa,²⁷² 2.1 kPa²⁷³). Encapsulated nerve cells also showed higher gene expression level of neural differentiation and neuron maturation markers including Synapsin1, β III-tubulin (TUBB3), and Neuronal nuclear antigen (NeuN) in softer matrices.²⁷² Similarly, greater spreading and branching of microvessels formed by ECs were observed with decreased matrix stiffness: from 17 to 7 kPa²⁷⁴ and from 0.5 Pa to 0.2 kPa.²⁷⁵ Additionally, stiffer matrices (~0.5 kPa) encourage EC spreading and branching versus softer matrices (~0.1 kPa).^{275,276} Though absolute stiffness ranges may vary due to divergent design parameters, generally more compliant matrices favor vascularization and innervation.

Cell migration and sprouting not only depend on the original matrix stiffness but also its degradation mode and rate.²⁷⁷⁻²⁷⁹ For example, our previous study found that matrix metalloproteinase (MMP)-degradable hydrogels better support EC sprouting

than hydrolytically degradable hydrogels with a similar initial modulus (~10 kPa).²⁸⁰ Additionally, endothelial^{281,282} and nerve^{283,284} tissues can sense their surrounding mechanical environment and secrete enzymes, such as MMPs, to degrade and remodel ECM dynamically. Indeed, softer matrices (~2 kPa) upregulated nerve cell expression of MMP-2 and MMP-3 compared to stiffer matrices (~3.5 kPa).²⁸⁵

An additional challenge for some craniofacial tissues, including cranial and alveolar bones, is the requirement for structural stability during tissue regeneration. Many current approaches include a stiff scaffold component that slowly resorbs as new bone is deposited and matures.²⁸⁶ For instance, design criteria for periodontal tissue scaffolds often include a “bone” component with a distinct design from PDL and cementum portions of the scaffold.²⁸⁷ Even if each component of such multiphasic scaffolds is porous and interconnected, ingrowth of host neurovasculature may be hindered by complex, slowly degrading structures. Thus, composite scaffolds that combine sufficiently porous or soft, degradable structures required for optimal neurovascularization together with stiffer, dense components that can direct bone growth and stability may be required in certain craniofacial locations.

4.2.3. Biomaterial Biochemical Cues for Neurovascularization.—Given the critical role of cell-secreted growth factors (GFs) in driving transplanted cell bioactivity, therapeutic factors can be used to promote neurovascularization. For example, delivery of NGF,²⁸⁸⁻²⁹⁰ GDNF,²⁹¹⁻²⁹³ and BDNF^{294,295} from synthetic nerve conduits improves axon regeneration *in vivo*. Previous studies have also demonstrated enhanced vascularization and bone regeneration by singular and dual delivery of VEGF,^{160,161} PDGF,²⁹⁶ and VEGF/BMP2.^{127,297} Furthermore, FGF delivery has been reported to improve neurogenesis,²⁹⁸ angiogenesis,²⁹⁹ and bone regeneration.^{300,301} Consequently, therapeutic cues for tissue engineered neurovascular approaches will likely include combinations of proangiogenic and neural growth factors, which necessitates further investigation to identify the critical growth factors and define the appropriate doses and temporal availabilities to achieve regenerative success.

While GFs can be physically encapsulated/immobilized into or absorbed on the surface of biomaterials, these approaches are susceptible to a fast or burst release of factors immediately after contact with physiological fluids.³⁰² For example, burst release of VEGF and BMP-2 from poly(L-lactic acid) (PLLA) scaffolds was observed only after 24 h postimplantation *in vivo*, and >80% of these growth factors were released after 14 days (Figure 6A).³⁰³ This temporal profile is unlikely to match any native GF release patterns, and GF bioactivity may be compromised by unstable release profiles.²⁴⁸ For example, in cranial defects, angiogenesis and reinnervation do not occur until 3–7 days after injury and then continue for up to 6 weeks (Figure 4). Covalent immobilization of GFs to biomaterials through carbodiimide,^{304,305} thiol–ene,^{250,252,253,306,307} and enzymatic^{307,308} conjugations can eliminate the possibility of initial burst release and has emerged as a promising approach for improved GF delivery kinetics. In this case, GF release depends on biomaterial degradation or hydrolytic or enzymatic cleavage of the bond between GFs and the biomaterial.^{32,250} Additionally, inspired by the natural interactions between ECM and GFs, bioaffinity tethering approaches have been applied for more controlled delivery

systems. For example, due to the interaction between GFs (e.g., BMP2, VEGF, and FGF-2) and heparin sulfate of the natural ECM, biomaterials have been decorated with heparin or heparin sulfate-mimetic molecules to bind GFs.^{290,309,310} The higher affinity of heparin-GF binding not only contributes to more extended and stable release profiles but also facilitates localized and spatially regulated signaling.^{309,311}

During regeneration, integrin transmembrane receptors mediate cell–substrate binding, which is critical for adhesion and migration.^{312,313} Apart from forming focal adhesions, binding between integrin subunits (α and β) and ECM ligands alters actin cytoskeleton structures and actively transduces biochemical and signaling cascades.³¹⁴ Therefore, biomaterials have been functionalized by ECM protein mimetic peptides specifically to encourage neurogenesis and angiogenesis. Laminin mimetic peptides (CDPGYIGSR or CSRARKQAA-SIKVAVSAD,³¹⁵ and YIGSR³¹⁶) immobilized within chitosan hydrogels have been reported to promote nerve regeneration *in vivo*. Additionally, the peptide, RGD, which is ubiquitously found within myriad extracellular matrix proteins, has been incorporated into poly(caprolactone)-based materials to promote SCs outgrowth *in vitro*³¹⁷ and axonal regeneration and functional recovery *in vivo*.³¹⁸ Laminin (YIGSR,³¹⁹ SIKVAV³²⁰) and collagen (e.g., GFOGER¹⁵⁹ and P15 (PQGIAGQRGVV)³²¹) mimetic peptides, along with RGD³²² have also been applied to stimulate angiogenesis *in vitro* and *in vivo*. Additionally, fibronectin-derived peptide REDV (GREDVY),³²³ osteopontin-derived peptide SVVYGLR,³²⁴ and VEGF-binding domain-derived peptide PRIP (DRVQRQ-TTTVVA)³²⁵ have been used to functionalize biomaterials to enhance angiogenesis *in vivo*.

4.2.4. New Approaches to Meet Biomaterials Design Requirements for Neurovascularization.—Recently, various techniques have been applied to fabricate complex, multicomponent biomaterials to better meet the demands for neurovascularization. For example, synthetic polymers, such as poly(caprolactone) (PCL), poly(dimethylsiloxane) (PDMS), and hydrogels can be fabricated into vascular^{326,327} and neuronal^{328,329} scaffolds using three-dimensional (3D) printing techniques. Perfusable 3D-printed vascular networks and porous neural scaffolds have been reported to support angiogenesis³³⁰⁻³³² and neurogenesis,^{328,333} respectively, *in vitro*. A 3D printed PCL scaffold doped with tricalcium phosphate (TCP) supported vascularized new bone formation in a rat calvarial defect model,³³⁴ where the microchannels in the scaffold facilitated diffusion of nutrients to printed cells, overcoming the diffusion limit of 100–200 μm for cell survival in engineered tissues.³³⁵ 3D printing has also been used to fabricate scaffolds for alveolar bone and periodontal tissue regeneration, primarily to localize growth factors and transplanted cells and guide cell orientation during healing.³³⁶ 3D printing technology is also being explored for salivary gland regeneration, focusing on secretory and duct cell patterning and organoid printing.³³⁷⁻³⁴⁰ The integration of nerves and vasculature is likely to be a key step in the full integration and successful regeneration of salivary gland tissue using these methods. Therefore, 3D bioprinting has promise for fabricating scaffolds for bone and dental tissues regeneration, which provide features targeting vascularization and innervation.

A combination of favorable biochemical and biomechanical cues can be achieved by designing materials to support and respond to tissue infiltration as required during neurovascularization and tissue regeneration. In particular, MMP-degradable hydrogels

are promising materials from which to develop neurovascularization strategies.³⁴¹ Both endothelial cell migration and vessel extension during angiogenesis and axonal outgrowth and pathfinding during innervation occur via degradation of the surrounding ECM by MMPs.^{342,343} MMP-degradable hydrogels can be optimized to support host tissue recruitment and integration by modifying the degradation kinetics of the MMP-susceptible linkages.^{167,240,344-346} Moreover, the potential of MMP-degradable hydrogels to improve both angiogenesis and neurogenesis has been investigated *in vitro*^{347,348} and *in vivo*.^{349,350} Indeed, our recent study demonstrated that a tissue engineered periosteum composed of MMP-degradable hydrogels improved allograft healing by promoting rapid innervation and vascularization (Figure 5).²⁸⁰ We have also found that MMP-degradable hydrogels improve the organization, apicobasal polarization, and retention of salivary gland acinar cell phenotype in tissue-mimetic culture systems.^{351,352}

As control over growth factor delivery from polymeric scaffolds is still challenging,³⁰³ various fabrication techniques, such as microsphere formation³⁵³ and electrospinning,^{354,355} have been investigated. The GF release kinetics from microspheres can be adjusted by altering the molecular weight and composition of the copolymer.³⁵⁶ A sustained 4-week release of NGF³⁵⁷ and up to 80-days of steady release of BDNF and GDNF³⁵⁸ (Figure 6B) from PLGA microspheres have been reported, where the release of NGF significantly enhanced neurite outgrowth *in vitro*. The *in vivo* release profile of BMP-2 from PLGA microspheres has been shown to be an S-shaped curve over 84 days without any observed burst release at early time points (Figure 6C).³⁵⁹ PLGA microspheres were also developed to exhibit minimal initial *in vitro* release of VEGF in the first 7 days after loading and then reaching a plateau at day 20.³⁵⁵

Another fabrication method to prolong the release of entrapped GFs is via electrospinning. Electrospinning techniques can manufacture scaffolds with ECM-like structure including variable degrees of porosity and adjustable mechanical properties.³⁶⁰ Growth factor release can be controlled by the extruded materials' orientation and geometries.³⁶¹ Electrospun PLGA nanofibers have been reported to slow the release of FGF-2³⁵⁴ and VEGF³⁵⁵ *in vitro*, showing a 28-day sustained *in vitro* release profile of VEGF (Figure 6D).

5. PERSPECTIVES ON NEUROVASCULARIZATION STRATEGIES FOR CRANIOFACIAL TISSUE REGENERATION

Despite great progress in the fundamental understanding of neurovascularization during development and regeneration and biomaterials design and fabrication, progress in implementing these innovations for the repair of craniofacial tissue defects is still in its infancy. Given the complex nature of craniofacial tissues, the integration of multiple tissues remains a critical barrier. For example, during craniofacial bone regeneration, osteogenic, neurogenic, and endothelial cells may require different microenvironments to holistically integrate to coordinate healing.^{158,362} Challenges in manipulating multiple cell types, particularly those originating from different tissues, as well as spatial regulation of complex cell-cell interactions, remain unaddressed.³⁶³ Additionally, the clinical translation of cell-based therapies can be hindered by complicated cell isolation processes, long-term

loss of viability, regulatory hurdles, and adverse host responses,³⁶⁴ some which may be overcome through the use of iPSCs and their offer of nearly infinite patient-specific cells and cell types.³⁶⁵ Successful neurovascularization strategies are also likely to require spatially and temporally regulated growth factor/bioactive peptide release. Considering the multifactorial and differential effects of growth factors on various cell types, a significant challenge is determining and delivering optimal combinations and concentrations of growth factors with appropriate temporal availabilities to coordinate successful craniofacial tissue regeneration.³⁶⁶ Nevertheless, recruitment of host neurovascular tissues can be modulated within tissue engineering approaches through careful design of biomaterial mechanics, degradation rate and mechanism (hydrolytic or enzymatic), and adhesive ligand concentration.^{148-150,367-370} MMP-degradable hydrogels,³⁴¹ incorporation of critical growth factors or iPSCs-derived target cells, prevascularization, and preinnervation strategies, as well as new tissue engineering techniques such as 3D printing, have promise for the development of biomaterials that can improve the regeneration of craniofacial tissues by promoting neurovascularization.

ACKNOWLEDGMENTS

This work was supported by the National Science Foundation (CAREER Award Nos. CBET1450987 and DMR2103553 (to D.S.W.B.), and DGE1419118 (to M.R.N.)), National Institutes of Health (NIH) P30 AR069655, R01 AR064200, R01 AR056696, R01 AR071363, UG3DE027695, and UH3 DE027695 (to D.S.W.B.), T32 ES007026 (to J.A.M.), and UL1 TR002001 (University of Rochester Clinical and Translational Science Institute Pilot Award to D.F.). D.F. is supported by the UR Joan Wright Goodman Dissertation Fellowship.

REFERENCES

- (1). Warren SM; Fong KD; Chen CM; Lobo EG; Cowan CM; Lorenz HP; Longaker MT Tools and techniques for craniofacial tissue engineering. *Tissue Eng.* 2003, 9 (2), 187–200. [PubMed: 12740082]
- (2). Petrovic V; Zivkovic P; Petrovic D; Stefanovic V Craniofacial bone tissue engineering. *Oral surgery, oral medicine, oral pathology and oral radiology* 2012, 114 (3), No. e1.
- (3). Zhang W; Yelick PC Craniofacial tissue engineering. *Cold Spring Harbor Perspect. Med* 2018, 8 (1), No. a025775.
- (4). Li J; Gsaxner C; Pepe A; Morais A; Alves V; von Campe G; Wallner J; Egger J Synthetic skull bone defects for automatic patient-specific craniofacial implant design. *Sci. Data* 2021, 8 (1), 1–8. [PubMed: 33414438]
- (5). Ozdemir D Dental caries: the most common disease worldwide and preventive strategies. *Int. J. Biol* 2013, 5 (4), 55.
- (6). Kinane DF; Stathopoulou PG; Papapanou PN Periodontal diseases. *Nat. Rev. Dis Primers* 2017, 3, 17038. [PubMed: 28805207]
- (7). Jasmer KJ; Gilman KE; Muñoz Forti K; Weisman GA; Limesand KH Radiation-Induced Salivary Gland Dysfunction: Mechanisms, Therapeutics and Future Directions. *J. Clin. Med* 2020, 9 (12), 4095.
- (8). Limesand KH; Said S; Anderson SM Suppression of Radiation-Induced Salivary Gland Dysfunction by IGF-1. *PLoS One* 2009, 4 (3), No. e4663. [PubMed: 19252741]
- (9). Konings AWT; Coppes RP; Vissink A On the mechanism of salivary gland radiosensitivity. *Int. J. Radiat. Oncol., Biol., Phys* 2005, 62 (4), 1187–1194. [PubMed: 15990024]
- (10). Szpalski C; Barr J; Wetterau M; Saadeh PB; Warren SM Cranial bone defects: current and future strategies. *Neurosurgical focus* 2010, 29 (6), E8.
- (11). Lovett M; Lee K; Edwards A; Kaplan DL Vascularization strategies for tissue engineering. *Tissue Eng., Part B* 2009, 15 (3), 353–370.

- (12). Kannan RY; Salacinski HJ; Sales K; Butler P; Seifalian AM The roles of tissue engineering and vascularisation in the development of micro-vascular networks: a review. *Biomaterials* 2005, 26 (14), 1857–75. [PubMed: 15576160]
- (13). Liu Y; Chan JK; Teoh SH Review of vascularised bone tissue-engineering strategies with a focus on co-culture systems. *J. Tissue Eng. Regener. Med* 2015, 9 (2), 85–105.
- (14). Roux BM; Cheng MH; Brey EM Engineering clinically relevant volumes of vascularized bone. *J. Cell. Mol. Med* 2015, 19 (5), 903–14. [PubMed: 25877690]
- (15). Kigami R; Sato S; Tsuchiya N; Sato N; Suzuki D; Arai Y; Ito K; Ogiso B Effect of basic fibroblast growth factor on angiogenesis and bone regeneration in non-critical-size bone defects in rat calvaria. *J. Oral Sci* 2014, 56 (1), 17–22. [PubMed: 24739703]
- (16). Shah NJ; Hyder MN; Quadir MA; Courchesne N-MD; Seeherman HJ; Nevins M; Spector M; Hammond PT Adaptive growth factor delivery from a polyelectrolyte coating promotes synergistic bone tissue repair and reconstruction. *Proc. Natl. Acad. Sci. U. S. A* 2014, 111 (35), 12847–12852. [PubMed: 25136093]
- (17). Huang GTJ; Yamaza T; Shea LD; Djouad F; Kuhn NZ; Tuan RS; Shi S Stem/Progenitor Cell-Mediated De Novo Regeneration of Dental Pulp with Newly Deposited Continuous Layer of Dentin in an In Vivo Model. *Tissue Eng., Part A* 2010, 16 (2), 605–615. [PubMed: 19737072]
- (18). Dissanayaka WL; Zhang C The Role of Vasculature Engineering in Dental Pulp Regeneration. *Journal of Endodontics* 2017, 43 (9), S102–S106. [PubMed: 28962902]
- (19). Huber AB; Kolodkin AL; Ginty DD; Cloutier JF Signaling at the growth cone: ligand-receptor complexes and the control of axon growth and guidance. *Annu. Rev. Neurosci* 2003, 26, 509–63. [PubMed: 12677003]
- (20). Scheib J; Hoke A Advances in peripheral nerve regeneration. *Nat. Rev. Neurol* 2013, 9 (12), 668–76. [PubMed: 24217518]
- (21). Alvites RD; Santos ARC; Varejão ASP; Maurício A Olfactory Mucosa Mesenchymal Stem Cells and Biomaterials: A New Combination to Regenerative Therapies after Peripheral Nerve Injury. *Mesenchymal Stem Cells—Isolation, Characterization and Applications* 2017, 55235.
- (22). Terenghi G Peripheral nerve regeneration and neurotrophic factors. *J. Anat* 1999, 194 (1), 1–14. [PubMed: 10227662]
- (23). Dickson BJ Molecular mechanisms of axon guidance. *Science* 2002, 298 (5600), 1959–64. [PubMed: 12471249]
- (24). Tessier-Lavigne M; Goodman CS The molecular biology of axon guidance. *Science* 1996, 274 (5290), 1123–33. [PubMed: 8895455]
- (25). Kannan S; Lee M; Muthusamy S; Blasiak A; Sriram G; Cao T Peripheral sensory neurons promote angiogenesis in neurovascular models derived from hESCs. *Stem Cell Res.* 2021, 52, 102231. [PubMed: 33601097]
- (26). Grasman JM; Kaplan DL Human endothelial cells secrete neurotrophic factors to direct axonal growth of peripheral nerves. *Sci. Rep* 2017, 7 (1), 1–12. [PubMed: 28127051]
- (27). Honma Y; Araki T; Gianino S; Bruce A; Heuckeroth R; Johnson E; Milbrandt J Artemin is a vascular-derived neurotrophic factor for developing sympathetic neurons. *Neuron* 2002, 35 (2), 267–82. [PubMed: 12160745]
- (28). Kuruvilla R; Zweifel LS; Glebova NO; Lonze BE; Valdez G; Ye H; Ginty DD A neurotrophin signaling cascade coordinates sympathetic neuron development through differential control of TrkA trafficking and retrograde signaling. *Cell* 2004, 118 (2), 243–55. [PubMed: 15260993]
- (29). Mukouyama YS; Shin D; Britsch S; Taniguchi M; Anderson DJ Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. *Cell* 2002, 109 (6), 693–705. [PubMed: 12086669]
- (30). Black JE; Isaacs KR; Anderson BJ; Alcantara AA; Greenough WT Learning causes synaptogenesis, whereas motor activity causes angiogenesis, in cerebellar cortex of adult rats. *Proc. Natl. Acad. Sci. U. S. A* 1990, 87 (14), 5568–72. [PubMed: 1695380]
- (31). Kokaia Z; Lindvall O Neurogenesis after ischaemic brain insults. *Curr. Opin. Neurobiol* 2003, 13 (1), 127–32. [PubMed: 12593991]
- (32). Van Hove AH; Benoit DS Depot-based delivery systems for pro-angiogenic peptides: a review. *Front. Bioeng. Biotechnol* 2015, 3, 102. [PubMed: 26236708]

- (33). Herskovits M; Hallas B; Singh I Study of sympathetic innervation of cranial bones by axonal transport of horseradish peroxidase in the rat: preliminary findings. *Cells Tissues Organs* 1993, 147 (3), 178–183.
- (34). Kosaras B; Jakubowski M; Kainz V; Burstein R Sensory innervation of the calvarial bones of the mouse. *J. Comp. Neurol* 2009, 515 (3), 331–348. [PubMed: 19425099]
- (35). Hill EL; Elde R Distribution of CGRP-, VIP-, $D\beta H$ -, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. *Cell Tissue Res.* 1991, 264 (3), 469–480. [PubMed: 1714353]
- (36). Hilkens P; Lambrechts I; Bronckaers A Current and Future Views on Pulpal Angiogenesis. In *Clinical Approaches in Endodontic Regeneration: Current and Emerging Therapeutic Perspectives*; Duncan HF, Cooper PR, Eds.; Springer International Publishing: Cham, 2019; pp 37–53.
- (37). Yu C; Abbott PV An overview of the dental pulp: its functions and responses to injury. *Aust. Dent. J* 2007, 52 (1 Suppl), S4–16.
- (38). Beertsen W; McCulloch CA; Sodek J The periodontal ligament: a unique, multifunctional connective tissue. *Periodontology* 2000 1997, 13, 20–40. [PubMed: 9567922]
- (39). Foster B; Somerman M Cementum. In *Mineralized Tissues in Oral and Craniofacial Science*; McCauley LK, Somerman MJ, Eds.; Wiley, 2013.
- (40). Kaukua N; Shahidi MK; Konstantinidou C; Dyachuk V; Kaucka M; Furlan A; An Z; Wang L; Hultman I; Ahrlund-Richter L; Blom H; Brismar H; Lopes NA; Pachnis V; Suter U; Clevers H; Thesleff I; Sharpe P; Ernfors P; Fried K; Adameyko I Glial origin of mesenchymal stem cells in a tooth model system. *Nature* 2014, 513 (7519), 551–4. [PubMed: 25079316]
- (41). Men Y; Wang Y; Yi Y; Jing D; Luo W; Shen B; Stenberg W; Chai Y; Ge W-P; Feng JQ; Zhao H Gli1+ Periodontium Stem Cells Are Regulated by Osteocytes and Occlusal Force. *Dev. Cell* 2020, 54 (5), 639–654. [PubMed: 32652075]
- (42). Zhao H; Feng J; Seidel K; Shi S; Klein O; Sharpe P; Chai Y Secretion of Shh by a Neurovascular Bundle Niche Supports Mesenchymal Stem Cell Homeostasis in the Adult Mouse Incisor. *Cell Stem Cell* 2014, 14 (2), 160–173. [PubMed: 24506883]
- (43). Kwon HR; Nelson DA; DeSantis KA; Morrissey JM; Larsen M Endothelial cell regulation of salivary gland epithelial patterning. *Development* 2017, 144 (2), 211–220. [PubMed: 28096213]
- (44). de Paula F; Teshima THN; Hsieh R; Souza MM; Nico MMS; Lourenco SV Overview of Human Salivary Glands: Highlights of Morphology and Developing Processes. *Anat. Rec* 2017, 300 (7), 1180–1188.
- (45). Knox SM; Lombaert IM; Reed X; Vitale-Cross L; Gutkind JS; Hoffman MP Parasympathetic innervation maintains epithelial progenitor cells during salivary organogenesis. *Science* 2010, 329 (5999), 1645–7. [PubMed: 20929848]
- (46). Holmberg KV; Hoffman MP Anatomy, biogenesis and regeneration of salivary glands. *Monogr Oral Sci.* 2014, 24, 1–13. [PubMed: 24862590]
- (47). Porcheri C; Mitsiadis TA Physiology, Pathology and Regeneration of Salivary Glands. *Cells* 2019, 8 (9), 976.
- (48). Carmeliet P Blood vessels and nerves: common signals, pathways and diseases. *Nat. Rev. Genet* 2003, 4 (9), 710–20. [PubMed: 12951572]
- (49). Carmeliet P; Tessier-Lavigne M Common mechanisms of nerve and blood vessel wiring. *Nature* 2005, 436 (7048), 193–200. [PubMed: 16015319]
- (50). Stegen S; van Gestel N; Carmeliet G Bringing new life to damaged bone: the importance of angiogenesis in bone repair and regeneration. *Bone* 2015, 70, 19–27. [PubMed: 25263520]
- (51). Marsell R; Einhorn TA The biology of fracture healing. *Injury* 2011, 42 (6), 551–5. [PubMed: 21489527]
- (52). Schindeler A; McDonald MM; Bokko P; Little DG Bone remodeling during fracture repair: The cellular picture. *Semin. Cell Dev. Biol* 2008, 19 (5), 459–66. [PubMed: 18692584]
- (53). Claes L; Recknagel S; Ignatius A Fracture healing under healthy and inflammatory conditions. *Nat. Rev. Rheumatol* 2012, 8 (3), 133–43. [PubMed: 22293759]
- (54). Ratko TA; Belinson SE; Samson DJ; Bonnell C; Ziegler KM; Aronson N Bone Morphogenetic Protein: The State of the Evidence of On-Label and Off-Label Use; Agency for Healthcare Research and Quality: Rockville, MD, 2010.

- (55). Kolar P; Gaber T; Perka C; Duda GN; Buttgerit F Human early fracture hematoma is characterized by inflammation and hypoxia. *Clin. Orthop. Relat. Res* 2011, 469 (11), 3118–3126. [PubMed: 21409457]
- (56). Wang J; Glimcher M Characterization of matrix-induced osteogenesis in rat calvarial bone defects: II. Origins of bone-forming cells. *Calcif. Tissue Int* 1999, 65 (6), 486–493. [PubMed: 10594169]
- (57). Zhang X Intravital imaging to understand spatiotemporal regulation of osteogenesis and angiogenesis in cranial defect repair and regeneration. In *Somatic Stem Cells*; Springer, 2018; pp 229–239.
- (58). Holstein J; Becker S; Fiedler M; Garcia P; Histing T; Klein M; Laschke M; Corsten M; Pohlemann T; Menger M Intravital microscopic studies of angiogenesis during bone defect healing in mice calvaria. *Injury* 2011, 42 (8), 765–771. [PubMed: 21156316]
- (59). Takano S; Uchida K; Miyagi M; Inoue G; Fujimaki H; Aikawa J; Iwase D; Minatani A; Iwabuchi K; Takaso M Nerve growth factor regulation by TNF- α and IL-1 β in synovial macrophages and fibroblasts in osteoarthritic mice. *J. Immunol. Res* 2016, 2016, 1.
- (60). Meyers CA; Lee S; Sono T; Xu J; Negri S; Tian Y; Wang Y; Li Z; Miller S; Chang L; et al. A neurotrophic mechanism directs sensory nerve transit in cranial bone. *Cell Rep.* 2020, 31 (8), 107696. [PubMed: 32460020]
- (61). Silva D The role of sensory nervous system in the regulation of bone formation, remodeling, and repair. *Human Health and Pathology*; Université de Bordeaux, 2017.
- (62). El Karim IA; Linden GJ; Irwin CR; Lundy FT Neuropeptides regulate expression of angiogenic growth factors in human dental pulp fibroblasts. *Journal of endodontics* 2009, 35 (6), 829–833. [PubMed: 19482180]
- (63). Aoki M; Tamai K; Saotome K Substance P-and calcitonin gene-related peptide-immunofluorescent nerves in the repair of experimental bone defects. *International orthopaedics* 1994, 18 (5), 317–324. [PubMed: 7531673]
- (64). Matsubara H; Hogan DE; Morgan EF; Mortlock DP; Einhorn TA; Gerstenfeld LC Vascular tissues are a primary source of BMP2 expression during bone formation induced by distraction osteogenesis. *Bone* 2012, 51 (1), 168–180. [PubMed: 22391215]
- (65). Hu K; Olsen BR Vascular endothelial growth factor control mechanisms in skeletal growth and repair. *Dev. Dyn* 2017, 246 (4), 227–234. [PubMed: 27750398]
- (66). Murray PE; Garcia-Godoy F; Hargreaves KM Regenerative Endodontics: A Review of Current Status and a Call for Action. *Journal of Endodontics* 2007, 33 (4), 377–390. [PubMed: 17368324]
- (67). Rombouts C; Giraud T; Jeanneau C; About I Pulp Vascularization during Tooth Development, Regeneration, and Therapy. *J. Dent. Res* 2017, 96 (2), 137–144. [PubMed: 28106505]
- (68). Caviedes-Bucheli J; Muñoz HR; Azuero-Holguín MM; Ulate E Neuropeptides in dental pulp: the silent protagonists. *J. Endod* 2008, 34 (7), 773–88. [PubMed: 18570980]
- (69). Diogenes A Trigeminal Sensory Neurons and Pulp Regeneration. *Journal of Endodontics* 2020, 46 (9), S71–S80. [PubMed: 32950198]
- (70). Morfis A; Sylaras SN; Georgopoulou M; Kernani M; Prountzos F Study of the apices of human permanent teeth with the use of a scanning electron microscope. *Oral Surg., Oral Med., Oral Pathol* 1994, 77 (2), 172–6. [PubMed: 8139836]
- (71). Aukhil I Biology of wound healing. *Periodontology* 2000 2000, 22 (1), 44–50. [PubMed: 11276515]
- (72). Tavelli L; Ravidá A; Barootchi S; Chambrone L; Giannobile WV Recombinant Human Platelet-Derived Growth Factor: A Systematic Review of Clinical Findings in Oral Regenerative Procedures. *JDR Clinical & Translational Research* 2021, 6 (2), 161–173. [PubMed: 32392438]
- (73). Del Fabbro M; Karanxha L; Panda S; Bucchi C; Nadathur Doraiswamy J; Sankari M; Ramamoorthi S; Varghese S; Taschieri S Autologous platelet concentrates for treating periodontal infrabony defects. *Cochrane Database Syst. Rev* 2018, 11, Cd011423. [PubMed: 30484284]
- (74). Youn SH; Sakuda M; Kurisu K; Wakisaka S Regeneration of periodontal primary afferents of the rat incisor following injury of the inferior alveolar nerve with special reference to

- neuropeptide Y-like immunoreactive primary afferents. *Brain Res.* 1997, 752 (1–2), 161–9. [PubMed: 9106452]
- (75). Kvinnsland I; Heyeraas KJ Effect of traumatic occlusion on CGRP and SP immunoreactive nerve fibre morphology in rat molar pulp and periodontium. *Histochemistry* 1992, 97 (2), 111–20. [PubMed: 1373126]
- (76). Kato J; Wakisaka S; Kurisu K Immunohistochemical changes in the distribution of nerve fibers in the periodontal ligament during an experimental tooth movement of the rat molar. *Cells Tissues Organs* 1996, 157 (1), 53–62.
- (77). Vandevska-Radunovic V; Kvinnsland S; Kvinnsland IH Effect of experimental tooth movement on nerve fibres immunoreactive to calcitonin gene-related peptide, protein gene product 9.5, and blood vessel density and distribution in rats. *Eur. J. Orthod* 1997, 19 (5), 517–29. [PubMed: 9386338]
- (78). Yamaguchi M; Nakajima R; Kasai K Mechanoreceptors, Nociceptors, and Orthodontic Tooth Movement. *Seminars in Orthodontics* 2012, 18 (4), 249–256.
- (79). Kondo M; Kondo H; Miyazawa K; Goto S; Togari A Experimental tooth movement-induced osteoclast activation is regulated by sympathetic signaling. *Bone* 2013, 52 (1), 39–47. [PubMed: 23000507]
- (80). Atsumi Y; Hayashi S; Nakakura-Ohshima K; Maeda T; Kurisu K; Wakisaka S Heterogeneous localizations of Trk B among individual periodontal Ruffini endings in the rat incisor. *Arch. Histol. Cytol* 1999, 62 (5), 435–40. [PubMed: 10678572]
- (81). Maeda T; Ochi K; Nakakura-Ohshima K; Youn SH; Wakisaka S The Ruffini ending as the primary mechanoreceptor in the periodontal ligament: its morphology, cytochemical features, regeneration, and development. *Crit. Rev. Oral Biol. Med* 1999, 10 (3), 307–27. [PubMed: 10759411]
- (82). Kurihara H; Shinohara H; Yoshino H; Takeda K; Shiba H Neurotrophins in cultured cells from periodontal tissues. *J. Periodontol* 2003, 74 (1), 76–84. [PubMed: 12593600]
- (83). Konishi A; Takeda K; Fujita T; Kajiyama M; Matsuda S; Kittaka M; Shiba H; Kurihara H Sequential process in brain-derived neurotrophic factor-induced functional periodontal tissue regeneration. *Eur. J. Oral Sci* 2016, 124 (2), 141–150. [PubMed: 26872052]
- (84). Xiong J; Gronthos S; Bartold PM Role of the epithelial cell rests of Malassez in the development, maintenance and regeneration of periodontal ligament tissues. *Periodontology* 2000 2013, 63 (1), 217–233. [PubMed: 23931062]
- (85). Yamashiro T; Fujiyama K; Fukunaga T; Wang Y; Takano-Yamamoto T Epithelial rests of Malassez express immunoreactivity of TrkA and its distribution is regulated by sensory nerve innervation. *J. Histochem. Cytochem* 2000, 48 (7), 979–984. [PubMed: 10858275]
- (86). Fujiyama K; Yamashiro T; Fukunaga T; Balam TA; Zheng L; Takano-Yamamoto T Denervation Resulting in Dento-Alveolar Ankylosis Associated with Decreased Malassez Epithelium. *J. Dent. Res* 2004, 83 (8), 625–629. [PubMed: 15271971]
- (87). Nedvetsky PI; Emmerson E; Finley JK; Ettinger A; Cruz-Pacheco N; Prochazka J; Haddox CL; Northrup E; Hodges C; Mostov KE; Hoffman MP; Knox SM Parasympathetic Innervation Regulates Tubulogenesis in the Developing Salivary Gland. *Dev. Cell* 2014, 30 (4), 449–462. [PubMed: 25158854]
- (88). Chatzeli L; Gaete M; Tucker AS Fgf10 and Sox9 are essential for the establishment of distal progenitor cells during mouse salivary gland development. *Development* 2017, 144 (12), 2294–2305. [PubMed: 28506998]
- (89). Emmerson E; May AJ; Nathan S; Cruz-Pacheco N; Lizama CO; Maliskova L; Zovein AC; Shen Y; Muench MO; Knox SM SOX2 regulates acinar cell development in the salivary gland. *eLife* 2017, 6, No. e26620. [PubMed: 28623666]
- (90). Emmerson E; May AJ; Berthoin L; Cruz-Pacheco N; Nathan S; Mattingly AJ; Chang JL; Ryan WR; Tward AD; Knox SM Salivary glands regenerate after radiation injury through SOX2-mediated secretory cell replacement. *EMBO Mol. Med* 2018, 10 (3), e8051 DOI: 10.15252/emmm.201708051. [PubMed: 29335337]

- (91). Duan X; Bradbury SR; Olsen BR; Berendsen AD VEGF stimulates intramembranous bone formation during craniofacial skeletal development. *Matrix Biol.* 2016, 52, 127–140. [PubMed: 26899202]
- (92). Kim J-M; Shin H-I; Cha S-S; Lee CS; Hong BS; Lim S; Jang H-J; Kim J; Yang YR; Kim Y-H; et al. DJ-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling. *Nat. Commun* 2012, 3 (1), 1–11.
- (93). Henmi A; Nakamura M; Echigo S; Sasano Y Involvement of sensory neurons in bone defect repair in rats. *J. Electron Microsc* 2011, 60 (6), 393–400.
- (94). Jones RE; Salhotra A; Robertson KS; Ransom RC; Foster DS; Shah HN; Quarto N; Wan DC; Longaker MT Skeletal stem cell-schwann cell circuitry in mandibular repair. *Cell Rep.* 2019, 28 (11), 2757–2766 e5. [PubMed: 31509739]
- (95). Yamashiro T; Fujiyama K; Fujiyoshi Y; Inaguma N; Takano-Yamamoto T Inferior alveolar nerve transection inhibits increase in osteoclast appearance during experimental tooth movement. *Bone* 2000, 26 (6), 663–669. [PubMed: 10831939]
- (96). Lv L; Wang Y; Zhang J; Zhang T; Li S Healing of periodontal defects and calcitonin gene related peptide expression following inferior alveolar nerve transection in rats. *J. Mol. Histol* 2014, 45 (3), 311–20. [PubMed: 24202439]
- (97). Yu X; Lv L; Zhang J; Zhang T; Xiao C; Li S Expression of neuropeptides and bone remodeling-related factors during periodontal tissue regeneration in denervated rats. *J. Mol. Histol* 2015, 46 (2), 195–203. [PubMed: 25663522]
- (98). Chiego DJ Jr.; Klein RM; Avery JK; Gruhl IM Denervation-induced changes in cell proliferation in the rat molar after wounding. *Anat. Rec* 1986, 214 (4), 348–352. [PubMed: 3706780]
- (99). Byers MR; Taylor PE Effect of Sensory Denervation on the Response of Rat Molar Pulp to Exposure Injury. *J. Dent. Res* 1993, 72 (3), 613–618. [PubMed: 8450121]
- (100). Kim Y; Hamada N; Takahashi Y; Sasaguri K; Tsukinoki K; Onozuka M; Sato S Cervical sympathectomy causes alveolar bone loss in an experimental rat model. *J. Periodontal Res* 2009, 44 (6), 695–703. [PubMed: 19453856]
- (101). Knox SM; Lombaert IM; Haddox CL; Abrams SR; Cotrim A; Wilson AJ; Hoffman MP Parasympathetic stimulation improves epithelial organ regeneration. *Nat. Commun* 2013, 4, 1494. [PubMed: 23422662]
- (102). Proctor GB; Carpenter GH Regulation of salivary gland function by autonomic nerves. *Auton. Neurosci* 2007, 133 (1), 3–18. [PubMed: 17157080]
- (103). Wang X; Li Z; Shao Q; Zhang C; Wang J; Han Z; Wang S; Qin L The intact parasympathetic nerve promotes submandibular gland regeneration through ductal cell proliferation. *Cell Proliferation* 2021, 54 (7), No. e13078. [PubMed: 34101282]
- (104). Chen W-H; Mao C.-q.; Zhuo L.-l.; Ong JL Beta-nerve growth factor promotes neurogenesis and angiogenesis during the repair of bone defects. *Neural Regener. Res* 2015, 10 (7), 1159.
- (105). Jin P; Yin F; Huang L; Zheng L; Zhao J; Zhang X Guangxi cobra venom-derived NGF promotes the osteogenic and therapeutic effects of porous BCP ceramic. *Exp. Mol. Med* 2017, 49 (4), No. e312. [PubMed: 28386125]
- (106). Yan XZ; Ge SH; Sun QF; Guo HM; Yang PS A pilot study evaluating the effect of recombinant human bone morphogenetic protein-2 and recombinant human beta-nerve growth factor on the healing of Class III furcation defects in dogs. *J. Periodontol* 2010, 81 (9), 1289–98. [PubMed: 20397902]
- (107). Takeda K; Shiba H; Mizuno N; Hasegawa N; Mouri Y; Hirachi A; Yoshino H; Kawaguchi H; Kurihara H Brain-derived neurotrophic factor enhances periodontal tissue regeneration. *Tissue Eng.* 2005, 11 (9–10), 1618–29. [PubMed: 16259615]
- (108). Ramalho I; Bergamo E; Lopes A; Medina-Cintrón C; Neiva R; Witek L; Coelho P Periodontal Tissue Regeneration Using Brain-Derived Neurotrophic Factor Delivered by Collagen Sponge. *Tissue Eng., Part A* 2019, 25 (15–16), 1072–1083. [PubMed: 30489221]
- (109). Jimbo R; Tovar N; Janal MN; Mousa R; Marin C; Yoo D; Teixeira HS; Anchieta RB; Bonfante EA; Konishi A; Takeda K; Kurihara H; Coelho PG The Effect of Brain-Derived Neurotrophic Factor on Periodontal Furcation Defects. *PLoS One* 2014, 9 (1), No. e84845. [PubMed: 24454754]

- (110). Jimbo R; Singer J; Tovar N; Marin C; Neiva R; Bonfante EA; Janal MN; Contamin H; Coelho PG Regeneration of the cementum and periodontal ligament using local BDNF delivery in class II furcation defects. *J. Biomed. Mater. Res., Part B* 2018, 106 (4), 1611–1617.
- (111). Takeda K; Sakai N; Shiba H; Nagahara T; Fujita T; Kajiya M; Iwata T; Matsuda S; Kawahara K; Kawaguchi H; Kurihara H Characteristics of high-molecular-weight hyaluronic acid as a brain-derived neurotrophic factor scaffold in periodontal tissue regeneration. *Tissue Eng., Part A* 2011, 17 (7–8), 955–67. [PubMed: 21091323]
- (112). Ma W; Lyu H; Pandya M; Gopinathan G; Luan X; Diekwisch TGH Successful Application of a Galanin-Coated Scaffold for Periodontal Regeneration. *J. Dent. Res* 2021, 100 (10), 1144–1152. [PubMed: 34328037]
- (113). Ferreira JNA; Zheng C; Lombaert IMA; Goldsmith CM; Cotrim AP; Symonds JM; Patel VN; Hoffman MP Neurturin Gene Therapy Protects Parasympathetic Function to Prevent Irradiation-Induced Murine Salivary Gland Hypofunction. *Mol. Ther.–Methods Clin. Dev* 2018, 9, 172–180. [PubMed: 29560384]
- (114). Vining KH; Lombaert IMA; Patel VN; Kibbey SE; Pradhan-Bhatt S; Witt RL; Hoffman MP Neurturin-containing laminin matrices support innervated branching epithelium from adult epithelial salspheres. *Biomaterials* 2019, 216, 119245. [PubMed: 31200143]
- (115). Losordo DW; Dimmeler S Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. *Circulation* 2004, 109 (21), 2487–91. [PubMed: 15173038]
- (116). Papanas N; Maltezos E Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? *Int. J. Lower Extremity Wounds* 2007, 6 (1), 37–53.
- (117). Yonamine Y; Matsuyama T; Sonomura T; Takeuchi H; Furuichi Y; Uemura M; Izumi Y; Noguchi K Effectable application of vascular endothelial growth factor to critical sized rat calvaria defects. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology* 2010, 109 (2), 225–231.
- (118). Peng H; Usas A; Olshanski A; Ho AM; Gearhart B; Cooper GM; Huard J VEGF improves, whereas sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis. *J. Bone Miner. Res* 2005, 20 (11), 2017–2027. [PubMed: 16234975]
- (119). Mullane EM; Dong Z; Sedgley CM; Hu JCC; Botero TM; Holland GR; Nör JE Effects of VEGF and FGF2 on the Revascularization of Severed Human Dental Pulp. *J. Dent. Res* 2008, 87 (12), 1144–1148. [PubMed: 19029083]
- (120). Yadlapati M; Bigueti C; Cavalla F; Nieves F; Bessey C; Bohluli P; Garlet GP; Letra A; Fakhouri WD; Silva RM Characterization of a Vascular Endothelial Growth Factor–loaded Bioresorbable Delivery System for Pulp Regeneration. *Journal of Endodontics* 2017, 43 (1), 77–83. [PubMed: 27939739]
- (121). Nabeshima CK; Valdivia JE; Caballero-Flores H; Arana-Chavez VE; Machado MEDL Immunohistological study of the effect of vascular Endothelial Growth Factor on the angiogenesis of mature root canals in rat molars. *J. Appl. Oral Sci* 2018, 26, e20170437 DOI: 10.1590/1678-7757-2017-0437. [PubMed: 29791567]
- (122). Li X; Ma C; Xie X; Sun H; Liu X Pulp regeneration in a full-length human tooth root using a hierarchical nanofibrous microsphere system. *Acta Biomater.* 2016, 35, 57–67. [PubMed: 26931056]
- (123). Sylven C; Hao XJ; Silva EA; Mansson-Broberg A; Grinnemo KH; Siddiqui AJ; Dellgren G; Wardell E; Brodin LA; Mooney DJ Angiogenic effects of sequential release of VEGF-A(165) and PDGF-BB with alginate hydrogels after myocardial infarction. *Cardiovasc. Res* 2007, 75 (1), 178–185. [PubMed: 17481597]
- (124). Mooney DJ; Chen RR; Silva EA; Yuen WW Spatiotemporal VEGF and PDGF delivery patterns blood vessel formation and maturation. *Pharm. Res* 2007, 24 (2), 258–264. [PubMed: 17191092]
- (125). Layman H; Sacasa M; Murphy AE; Murphy AM; Pham SM; Andreopoulos FM Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model. *Acta Biomater.* 2009, 5 (1), 230–239. [PubMed: 18713669]
- (126). Brudno Y; Ennett-Shepard AB; Chen RR; Aizenberg M; Mooney DJ Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors. *Biomaterials* 2013, 34 (36), 9201–9209. [PubMed: 23972477]

- (127). Patel ZS; Young S; Tabata Y; Jansen JA; Wong ME; Mikos AG Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. *Bone* 2008, 43 (5), 931–940. [PubMed: 18675385]
- (128). Liu K; Meng C-X; Lv Z-Y; Zhang Y-J; Li J; Li K-Y; Liu F-Z; Zhang B; Cui F-Z Enhancement of BMP-2 and VEGF carried by mineralized collagen for mandibular bone regeneration. *Regenerative Biomaterials* 2020, 7 (4), 435–440. [PubMed: 32793388]
- (129). Kim JY; Xin X; Moiola EK; Chung J; Lee CH; Chen M; Fu SY; Koch PD; Mao JJ Regeneration of dental-pulp-like tissue by chemotaxis-induced cell homing. *Tissue Eng., Part A* 2010, 16 (10), 3023–31. [PubMed: 20486799]
- (130). Behr B; Leucht P; Longaker MT; Quarto N Fgf-9 is required for angiogenesis and osteogenesis in long bone repair. *Proc. Natl. Acad. Sci. U. S. A* 2010, 107 (26), 11853–8. [PubMed: 20547837]
- (131). Huang JY; Lynn Miskus M; Lu HC FGF-FGFR Mediates the Activity-Dependent Dendritogenesis of Layer IV Neurons during Barrel Formation. *J. Neurosci* 2017, 37 (50), 12094–12105. [PubMed: 29097598]
- (132). Nam K; Dean SM; Brown CT; Smith RJ Jr.; Lei P; Andreadis ST; Baker OJ Synergistic effects of laminin-1 peptides, VEGF and FGF9 on salivary gland regeneration. *Acta Biomater.* 2019, 91, 186–194. [PubMed: 31028910]
- (133). Laham RJ; Rezaee M; Post M; Sellke FW; Braeckman RA; Hung D; Simons M Intracoronary and intravenous administration of basic fibroblast growth factor: Myocardial and tissue distribution. *Drug Metab. Dispos* 1999, 27 (7), 821–826. [PubMed: 10383927]
- (134). Ozawa CR; Banfi A; Glazer NL; Thurston G; Springer ML; Kraft PE; McDonald DM; Blau HM Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. *J. Clin. Invest* 2004, 113 (4), 516–27. [PubMed: 14966561]
- (135). Silva EA; Mooney DJ Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. *J. Thromb. Haemostasis* 2007, 5 (3), 590–598. [PubMed: 17229044]
- (136). Liu Y; Chan JK; Teoh SH Review of vascularised bone tissue-engineering strategies with a focus on co-culture systems. *J. Tissue Eng. Regen. Med* 2015, 9 (2), 85–105.
- (137). Lehninger AL; Nelson DL; Cox MM *Lehninger principles of biochemistry*, 3rd ed.; Worth Publishers: New York, 2000.
- (138). Finetti F; Basile A; Capasso D; Di Gaetano S; Di Stasi R; Pascale M; Turco CM; Ziche M; Morbidelli L; D'Andrea LD Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. *Biochem. Pharmacol* 2012, 84 (3), 303–311. [PubMed: 22554565]
- (139). Shi L; Feng L; Zhu M-L; Yang Z-M; Wu T-Y; Xu J; Liu Y; Lin W-P; Lo JHT; Zhang J-F; et al. Vasoactive intestinal peptide stimulates bone marrow-mesenchymal stem cells osteogenesis differentiation by activating Wnt/ β -catenin signaling pathway and promotes rat skull defect repair. *Stem Cells Dev.* 2020, 29 (10), 655–666. [PubMed: 32070222]
- (140). Siddiqui Z; Sarkar B; Kim KK; Kadincesme N; Paul R; Kumar A; Kobayashi Y; Roy A; Choudhury M; Yang J; Shimizu E; Kumar VA Angiogenic hydrogels for dental pulp revascularization. *Acta Biomater.* 2021, 126, 109. [PubMed: 33689817]
- (141). Shang L; Liu Z; Ma B; Shao J; Wang B; Ma C; Ge S Dimethylallyl glycine/nanosilicates-loaded osteogenic/angiogenic difunctional fibrous structure for functional periodontal tissue regeneration. *Bioactive Materials* 2021, 6 (4), 1175–1188. [PubMed: 33163699]
- (142). Chen YC; Lin RZ; Qi H; Yang Y; Bae H; Melero-Martin JM; Khademhosseini A Functional Human Vascular Network Generated in Photocrosslinkable Gelatin Methacrylate Hydrogels. *Adv. Funct. Mater* 2012, 22 (10), 2027–2039. [PubMed: 22907987]
- (143). Chwalek K; Tsurkan MV; Freudenberg U; Werner C Glycosaminoglycan-based hydrogels to modulate heterocellular communication in in vitro angiogenesis models. *Sci. Rep* 2015, 4, 4414.
- (144). Culver JC; Hoffmann JC; Poche RA; Slater JH; West JL; Dickinson ME Three-dimensional biomimetic patterning in hydrogels to guide cellular organization. *Adv. Mater* 2012, 24 (17), 2344–8. [PubMed: 22467256]

- (145). Kusuma S; Shen YI; Hanjaya-Putra D; Mali P; Cheng L; Gerecht S Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix. *Proc. Natl. Acad. Sci. U. S. A* 2013, 110 (31), 12601–6. [PubMed: 23858432]
- (146). Leslie-Barbick JE; Moon JJ; West JL Covalently-immobilized vascular endothelial growth factor promotes endothelial cell tubulogenesis in poly(ethylene glycol) diacrylate hydrogels. *J. Biomater. Sci., Polym. Ed* 2009, 20 (12), 1763–79. [PubMed: 19723440]
- (147). Moon JJ; Saik JE; Poche RA; Leslie-Barbick JE; Lee SH; Smith AA; Dickinson ME; West JL Biomimetic hydrogels with pro-angiogenic properties. *Biomaterials* 2010, 31 (14), 3840–7. [PubMed: 20185173]
- (148). Nguyen EH; Zanutelli MR; Schwartz MP; Murphy WL Differential effects of cell adhesion, modulus and VEGFR-2 inhibition on capillary network formation in synthetic hydrogel arrays. *Biomaterials* 2014, 35 (7), 2149–61. [PubMed: 24332391]
- (149). Turturro MV; Christenson MC; Larson JC; Young DA; Brey EM; Papavasiliou G MMP-sensitive PEG diacrylate hydrogels with spatial variations in matrix properties stimulate directional vascular sprout formation. *PLoS One* 2013, 8 (3), No. e58897. [PubMed: 23554954]
- (150). Zisch AH; Lutolf MP; Ehrbar M; Raeber GP; Rizzi SC; Davies N; Schmokel H; Bezuidenhout D; Djonov V; Zilla P; Hubbell JA Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. *FASEB J.* 2003, 17 (15), 2260–2. [PubMed: 14563693]
- (151). Katata C; Sasaki JI; Li A; Abe GL; Nör JE; Hayashi M; Imazato S Fabrication of Vascularized DPSC Constructs for Efficient Pulp Regeneration. *J. Dent. Res* 2021, 100, 1351. [PubMed: 33913364]
- (152). Zhang D; Gao P; Li Q; Li J; Li X; Liu X; Kang Y; Ren L Engineering biomimetic periosteum with β -TCP scaffolds to promote bone formation in calvarial defects of rats. *Stem Cell Res. Ther* 2017, 8 (1), 1–11. [PubMed: 28057078]
- (153). Koike N; Fukumura D; Gralla O; Au P; Schechner JS; Jain RK Tissue engineering: creation of long-lasting blood vessels. *Nature* 2004, 428 (6979), 138–9. [PubMed: 15014486]
- (154). Zanutelli MR; Ardalani H; Zhang J; Hou Z; Nguyen EH; Swanson S; Nguyen BK; Bolin J; Elwell A; Bischel LL; Xie AW; Stewart R; Beebe DJ; Thomson JA; Schwartz MP; Murphy WL Stable engineered vascular networks from human induced pluripotent stem cell-derived endothelial cells cultured in synthetic hydrogels. *Acta Biomater.* 2016, 35, 32–41. [PubMed: 26945632]
- (155). Roux BM; Akar B; Zhou W; Stojkova K; Barrera B; Brankov J; Brey EM Preformed vascular networks survive and enhance vascularization in critical sized cranial defects. *Tissue Eng. Part A* 2018, 24 (21–22), 1603–1615. [PubMed: 30019616]
- (156). Das S; Browne KD; Laimo FA; Maggiore JC; Kaisaier H; Aguilar CA; Ali ZS; Moukioti F; Cullen DK, Pre-innervated Tissue Engineered Muscle Promotes a Pro-Regenerative Microenvironment Following Volumetric Muscle Loss. *bioRxiv* 2019. DOI: 10.1101/840124
- (157). Wu Y; Jing D; Ouyang H; Li L; Zhai M; Li Y; Bi L; Guoxian P Pre-implanted sensory nerve could enhance the neurotization in tissue-engineered bone graft. *Tissue Eng., Part A* 2015, 21 (15–16), 2241–2249. [PubMed: 25996367]
- (158). Marrella A; Lee TY; Lee DH; Karthedom S; Syla D; Chawla A; Khademhosseini A; Jang HL Engineering vascularized and innervated bone biomaterials for improved skeletal tissue regeneration. *Mater. Today* 2018, 21 (4), 362–376.
- (159). García JR; Clark AY; García AJ Integrin-specific hydrogels functionalized with VEGF for vascularization and bone regeneration of critical-size bone defects. *J. Biomed. Mater. Res., Part A* 2016, 104 (4), 889–900.
- (160). Leach JK; Kaigler D; Wang Z; Krebsbach PH; Mooney DJ Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration. *Biomaterials* 2006, 27 (17), 3249–3255. [PubMed: 16490250]
- (161). Kaigler D; Wang Z; Horger K; Mooney DJ; Krebsbach PH VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects. *J. Bone Miner. Res* 2006, 21 (5), 735–744. [PubMed: 16734388]

- (162). Chen SY; Qin JJ; Wang L; Mu TW; Jin D; Jiang S; Zhao PR; Pei GX Different effects of implanting vascular bundles and sensory nerve tracts on the expression of neuropeptide receptors in tissue-engineered bone in vivo. *Biomed. Mater* 2010, 5 (5), 055002. [PubMed: 20826910]
- (163). Cui JD; Pei GX; Jiang S [A study of the different effect on the expression of calcitonin gene related peptide and neuropeptide Y in tissue engineered bone with vascular bundle graft in vivo and that with sensory nerve tract graft in vivo]. *Zhonghua Wai Ke Za Zhi* 2008, 46 (16), 1249–52. [PubMed: 19094602]
- (164). Feng L; Lingling E; Liu H The effects of separating inferior alveolar neurovascular bundles on osteogenesis of tissue-engineered bone and vascularization. *Biomed. Pap* 2015, 159 (4), 637–41.
- (165). Wu Y; Jing D; Ouyang H; Li L; Zhai M; Li Y; Bi L; Guoxian P Pre-implanted Sensory Nerve Could Enhance the Neurotization in Tissue-Engineered Bone Graft. *Tissue Eng., Part A* 2015, 21 (15–16), 2241–9. [PubMed: 25996367]
- (166). Gu Y; Zhu J; Xue C; Li Z; Ding F; Yang Y; Gu X Chitosan/silk fibroin-based, Schwann cell-derived extracellular matrix-modified scaffolds for bridging rat sciatic nerve gaps. *Biomaterials* 2014, 35 (7), 2253–2263. [PubMed: 24360577]
- (167). Freudenberg U; Hermann A; Welzel PB; Stirl K; Schwarz SC; Grimmer M; Zieris A; Panyanuwat W; Zschoche S; Meinhold D; et al. A star-PEG–heparin hydrogel platform to aid cell replacement therapies for neurodegenerative diseases. *Biomaterials* 2009, 30 (28), 5049–5060. [PubMed: 19560816]
- (168). Hsieh S-C; Chang C-J; Cheng W-T; Tseng T-C; Hsu S.-h. Effect of an epineurial-like biohybrid nerve conduit on nerve regeneration. *Cell Transplant* 2016, 25 (3), 559–574. [PubMed: 26300431]
- (169). Johnson BN; Lancaster KZ; Zhen G; He J; Gupta MK; Kong YL; Engel EA; Krick KD; Ju A; Meng F; et al. 3D printed anatomical nerve regeneration pathways. *Adv. Funct. Mater* 2015, 25 (39), 6205–6217. [PubMed: 26924958]
- (170). García JR; García AJ Biomaterial-mediated strategies targeting vascularization for bone repair. *Drug Delivery Transl. Res* 2016, 6 (2), 77–95.
- (171). Archibald SJ; Krarup C; Shefner J; Li ST; Madison RD A collagen-based nerve guide conduit for peripheral nerve repair: An electrophysiological study of nerve regeneration in rodents and nonhuman primates. *J. Comp. Neurol* 1991, 306 (4), 685–696. [PubMed: 2071700]
- (172). Guan S; Zhang X-L; Lin X-M; Liu T-Q; Ma X-H; Cui Z-F Chitosan/gelatin porous scaffolds containing hyaluronic acid and heparan sulfate for neural tissue engineering. *J. Biomater. Sci., Polym. Ed* 2013, 24 (8), 999–1014. [PubMed: 23647254]
- (173). Hanjaya-Putra D; Yee J; Ceci D; Truitt R; Yee D; Gerecht S Vascular endothelial growth factor and substrate mechanics regulate in vitro tubulogenesis of endothelial progenitor cells. *Journal of cellular and molecular medicine* 2010, 14 (10), 2436–2447. [PubMed: 19968735]
- (174). Rosso G; Young P; Shahin V Mechanosensitivity of embryonic neurites promotes their directional extension and Schwann cells progenitors migration. *Cell. Physiol. Biochem* 2017, 44 (4), 1263–1270. [PubMed: 29183014]
- (175). Xu Y; Zhang Z; Chen X; Li R; Li D; Feng SA silk fibroin/collagen nerve scaffold seeded with a co-culture of Schwann cells and adipose-derived stem cells for sciatic nerve regeneration. *PLoS One* 2016, 11 (1), No. e0147184. [PubMed: 26799619]
- (176). Arslantunali D; Dursun T; Yucel D; Hasirci N; Hasirci V Peripheral nerve conduits: technology update. *Med. Devices: Evidence Res* 2014, 7, 405.
- (177). Zaidi M; Alam A; Bax B; Shankar V; Bax C; Gill J; Pazianas M; Huang C-H; Sahinoglu T; Moonga B; et al. Role of the endothelial cell in osteoclast control: new perspectives. *Bone* 1993, 14 (2), 97–102. [PubMed: 8392855]
- (178). Lamalice L; Le Boeuf F; Huot J Endothelial cell migration during angiogenesis. *Circ. Res* 2007, 100 (6), 782–794. [PubMed: 17395884]
- (179). Evans GR; Brandt K; Katz S; Chauvin P; Otto L; Bogle M; Wang B; Meszlenyi RK; Lu L; Mikos AG; et al. Bioactive poly (L-lactic acid) conduits seeded with Schwann cells for peripheral nerve regeneration. *Biomaterials* 2002, 23 (3), 841–848. [PubMed: 11774850]

- (180). Schlosshauer B; Müller E; Schröder B; Planck H; Müller H-W Rat Schwann cells in bioresorbable nerve guides to promote and accelerate axonal regeneration. *Brain Res.* 2003, 963 (1–2), 321–326. [PubMed: 12560139]
- (181). Rajaram A 3D Bioprinted hydrogel scaffolds laden with schwann cells for use as nerve repair conduits, Thesis, University of Saskatchewan, 2015.
- (182). Santos MI; Tuzlakoglu K; Fuchs S; Gomes ME; Peters K; Unger RE; Piskin E; Reis RL; Kirkpatrick CJ Endothelial cell colonization and angiogenic potential of combined nano-and microfibrinous scaffolds for bone tissue engineering. *Biomaterials* 2008, 29 (32), 4306–4313. [PubMed: 18706689]
- (183). Yu H; VandeVord PJ; Mao L; Matthew HW; Wooley PH; Yang S-Y Improved tissue-engineered bone regeneration by endothelial cell mediated vascularization. *Biomaterials* 2009, 30 (4), 508–517. [PubMed: 18973938]
- (184). Fedorovich NE; Haverslag RT; Dhert WJ; Alblas J The role of endothelial progenitor cells in prevascularized bone tissue engineering: development of heterogeneous constructs. *Tissue Eng., Part A* 2010, 16 (7), 2355–2367. [PubMed: 20205515]
- (185). Zhou LN; Wang JC; Zilundu PLM; Wang YQ; Guo WP; Zhang SX; Luo H; Zhou JH; Deng RD; Chen DF A comparison of the use of adipose-derived and bone marrow-derived stem cells for peripheral nerve regeneration in vitro and in vivo. *Stem Cell Res. Ther* 2020, 11, 1–16. [PubMed: 31900237]
- (186). Yang E.-z.; Zhang G.-w.; Xu J.-g.; Chen S; Wang H; Cao L.-l.; Liang B; Lian X.-f. Multichannel polymer scaffold seeded with activated Schwann cells and bone mesenchymal stem cells improves axonal regeneration and functional recovery after rat spinal cord injury. *Acta Pharmacol. Sin* 2017, 38 (5), 623–637. [PubMed: 28392569]
- (187). Kaigler D; Krebsbach PH; West ER; Horger K; Huang Y-C; Mooney DJ Endothelial cell modulation of bone marrow stromal cell osteogenic potential. *FASEB J.* 2005, 19 (6), 1–26. [PubMed: 15629889]
- (188). Tsigkou O; Pomerantseva I; Spencer JA; Redondo PA; Hart AR; O’Doherty E; Lin Y; Friedrich CC; Daheron L; Lin CP; et al. Engineered vascularized bone grafts. *Proc. Natl. Acad. Sci. U. S. A* 2010, 107 (8), 3311–3316. [PubMed: 20133604]
- (189). Mercado-Pagán ÁE; Kang Y; Park S; Yao J; Bishop J; Yang YP; et al. Synthesis and characterization of novel elastomeric poly (D, L-lactide urethane) maleate composites for bone tissue engineering. *Eur. Polym. J* 2013, 49 (10), 3337–3349. [PubMed: 24817764]
- (190). Kang Y; Ren L; Yang Y Engineering vascularized bone grafts by integrating a biomimetic periosteum and β -TCP scaffold. *ACS Appl Mater. Interfaces* 2014, 6 (12), 9622–9633. [PubMed: 24858072]
- (191). Khayat A; Monteiro N; Smith EE; Pagni S; Zhang W; Khademhosseini A; Yelick PC GelMA-Encapsulated hDPSCs and HUVECs for Dental Pulp Regeneration. *J. Dent. Res* 2017, 96 (2), 192–199. [PubMed: 28106508]
- (192). Dissanayaka WL; Zhu L; Hargreaves KM; Jin L; Zhang C Scaffold-free Prevascularized Microtissue Spheroids for Pulp Regeneration. *J. Dent. Res* 2014, 93 (12), 1296–1303. [PubMed: 25201919]
- (193). Kingham PJ; Kalbermatten DF; Mahay D; Armstrong SJ; Wiberg M; Terenghi G Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote neurite outgrowth in vitro. *Exp. Neurol* 2007, 207 (2), 267–274. [PubMed: 17761164]
- (194). Wei Y; Gong K; Zheng Z; Liu L; Wang A; Zhang L; Ao Q; Gong Y; Zhang X Schwann-like cell differentiation of rat adipose-derived stem cells by indirect co-culture with Schwann cells in vitro. *Cell Proliferation* 2010, 43 (6), 606–616. [PubMed: 21039999]
- (195). Khaki M; Salmanian AH; Abtahi H; Ganji A; Mosayebi G Mesenchymal stem cells differentiate to endothelial cells using recombinant vascular endothelial growth factor–A. *Rep. Biochem. Mol. Biol* 2018, 6 (2), 144. [PubMed: 29761109]
- (196). Shang T; Li S; Zhang Y; Lu L; Cui L; Guo FF Hypoxia promotes differentiation of adipose-derived stem cells into endothelial cells through demethylation of ephrinB2. *Stem Cell Res. Ther* 2019, 10 (1), 1–12. [PubMed: 30606242]

- (197). Aguirre A; Planell J; Engel E Dynamics of bone marrow–derived endothelial progenitor cell/ mesenchymal stem cell interaction in co-culture and its implications in angiogenesis. *Biochem. Biophys. Res. Commun* 2010, 400 (2), 284–291. [PubMed: 20732306]
- (198). Au P; Tam J; Fukumura D; Jain RK Bone marrow–derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. *Blood* 2008, 111 (9), 4551–4558. [PubMed: 18256324]
- (199). Dimitriou R; Tsiridis E; Giannoudis PV Current concepts of molecular aspects of bone healing. *Injury* 2005, 36 (12), 1392–1404. [PubMed: 16102764]
- (200). Huang NF; Li S Mesenchymal stem cells for vascular regeneration. *Regener. Med* 2008, 3, 877.
- (201). Khayat A; Monteiro N; Smith E; Pagni S; Zhang W; Khademhosseini A; Yelick P GelMA-encapsulated hDPSCs and HUVECs for dental pulp regeneration. *J. Dent. Res* 2017, 96 (2), 192–199. [PubMed: 28106508]
- (202). Lin W; Chen M; Hu C; Qin S; Chu C; Xiang L; Man Y; Qu Y Endowing ipsc-derived mscs with angiogenic and keratinogenic differentiation potential: A promising cell source for skin tissue engineering. *BioMed Res. Int* 2018, 2018, 1.
- (203). Lo B; Parham L Ethical issues in stem cell research. *Endocr. Rev* 2009, 30 (3), 204–213. [PubMed: 19366754]
- (204). Lai W-H; Ho JC; Chan Y-C; Ng JH; Au K-W; Wong L-Y; Siu C-W; Tse H-F Attenuation of hind-limb ischemia in mice with endothelial-like cells derived from different sources of human stem cells. *PLoS One* 2013, 8 (3), No. e57876. [PubMed: 23472116]
- (205). Faiz M; Nagy A Induced pluripotent stem cells and disorders of the nervous system: progress, problems, and prospects. *Neuroscientist* 2013, 19 (6), 567–577. [PubMed: 23797497]
- (206). Park TS; Bhutto I; Zimmerlin L; Huo JS; Nagaria P; Miller D; Rufaihah AJ; Talbot C; Aguilar J; Grebe R; et al. Vascular progenitors from cord blood-derived iPSC possess augmented capacity for regenerating ischemic retinal vasculature. *Circulation* 2014, 129 (3), 359. [PubMed: 24163065]
- (207). Kim KL; Song S-H; Choi K-S; Suh W Cooperation of endothelial and smooth muscle cells derived from human induced pluripotent stem cells enhances neovascularization in dermal wounds. *Tissue Eng., Part A* 2013, 19 (21–22), 2478–2485. [PubMed: 23790124]
- (208). Huang C-W; Huang W-C; Qiu X; Da Silva FFF; Wang A; Patel S; Nesti LJ; Poo M-M; Li S The differentiation stage of transplanted stem cells modulates nerve regeneration. *Sci. Rep* 2017, 7 (1), 1–12. [PubMed: 28127051]
- (209). Csobonyeiova M; Polak S; Zamborsky R; Danisovic L iPSC cell technologies and their prospect for bone regeneration and disease modeling: a mini review. *Journal of advanced research* 2017, 8 (4), 321–327. [PubMed: 28386481]
- (210). Xu X; Liao L; Tian W Strategies of Prevascularization in Tissue Engineering and Regeneration of Craniofacial Tissues. *Tissue Eng., Part B* 2021. DOI: 10.1089/ten.teb.2021.0004
- (211). Radwan IA; Rady D; Abbass M; El Moshy S; AbuBakr N; Dorfer CE; Fawzy El-Sayed KM Induced pluripotent stem cells in dental and nondental tissue regeneration: a review of an unexploited potential. *Stem Cells Int.* 2020, 2020, 1.
- (212). Wang S; Cai L Polymers for fabricating nerve conduits. *Int. J. Polym. Sci* 2010, 2010, 1.
- (213). Das KK; Srivastava AK Nerve conduits as replacements of autografts in peripheral nerve surgery: Still a work in progress. *Neurol. India* 2019, 67 (7), 115. [PubMed: 30860107]
- (214). Heath CA; Rutkowski GE The development of bioartificial nerve grafts for peripheral-nerve regeneration. *Trends Biotechnol.* 1998, 16 (4), 163–168. [PubMed: 9586239]
- (215). Bellamkonda RV Peripheral nerve regeneration: an opinion on channels, scaffolds and anisotropy. *Biomaterials* 2006, 27 (19), 3515–3518. [PubMed: 16533522]
- (216). Evans GR Challenges to nerve regeneration, *Semin Surg Oncol*; Wiley Online Library, 2000; pp 312–318.
- (217). Yao Y; Cui Y; Zhao Y; Xiao Z; Li X; Han S; Chen B; Fang Y; Wang P; Pan J; et al. Effect of longitudinally oriented collagen conduit combined with nerve growth factor on nerve regeneration after dog sciatic nerve injury. *J. Biomed. Mater. Res., Part B* 2018, 106 (6), 2131–2139.

- (218). di Summa PG; Kalbermatten DF; Pralong E; Raffoul W; Kingham PJ; Terenghi G Long-term in vivo regeneration of peripheral nerves through bioengineered nerve grafts. *Neuroscience* 2011, 181, 278–291. [PubMed: 21371534]
- (219). Ceballos D; Navarro X; Dubey N; Wendelschafer-Crabb G; Kennedy WR; Tranquillo RT Magnetically aligned collagen gel filling a collagen nerve guide improves peripheral nerve regeneration. *Exp. Neurol* 1999, 158 (2), 290–300. [PubMed: 10415137]
- (220). Gonzalez-Perez F; Cobianchi S; Heimann C; Phillips JB; Udina E; Navarro X Stabilization, rolling, and addition of other extracellular matrix proteins to collagen hydrogels improve regeneration in chitosan guides for long peripheral nerve gaps in rats. *Neurosurgery* 2017, 80 (3), 465–474. [PubMed: 28362971]
- (221). Alhosseini SN; Moztaazadeh F; Mozafari M; Asgari S; Dodel M; Samadikuchaksaraei A; Kargozar S; Jalali N Synthesis and characterization of electrospun polyvinyl alcohol nanofibrous scaffolds modified by blending with chitosan for neural tissue engineering. *Int. J. Nanomed* 2012, 7, 25.
- (222). Gonzalez-Perez F; Cobianchi S; Geuna S; Barwig C; Freier T; Udina E; Navarro X Tubulization with chitosan guides for the repair of long gap peripheral nerve injury in the rat. *Microsurg* 2015, 35 (4), 300–308.
- (223). Malafaya PB; Santos TC; van Griensven M; Reis RL Morphology, mechanical characterization and in vivo neovascularization of chitosan particle aggregated scaffolds architectures. *Biomaterials* 2008, 29 (29), 3914–3926. [PubMed: 18649938]
- (224). Deng W-S; Ma K; Liang B; Liu X-Y; Xu H-Y; Zhang J; Shi H-Y; Sun H-T; Chen X-Y; Zhang S Collagen scaffold combined with human umbilical cord-mesenchymal stem cells transplantation for acute complete spinal cord injury. *Neural Regener. Res* 2020, 15 (9), 1686.
- (225). Shen YH; Shoichet MS; Radisic M Vascular endothelial growth factor immobilized in collagen scaffold promotes penetration and proliferation of endothelial cells. *Acta Biomater.* 2008, 4 (3), 477–489. [PubMed: 18328795]
- (226). Moore AM; Kasukurthi R; Magill CK; Farhadi HF; Borschel GH; Mackinnon SE Limitations of conduits in peripheral nerve repairs. *Hand* 2009, 4 (2), 180–186. [PubMed: 19137378]
- (227). Wang X; Hu W; Cao Y; Yao J; Wu J; Gu X Dog sciatic nerve regeneration across a 30-mm defect bridged by a chitosan/PGA artificial nerve graft. *Brain* 2005, 128 (8), 1897–1910. [PubMed: 15872018]
- (228). Matsumoto K; Ohnishi K; Kiyotani T; Sekine T; Ueda H; Nakamura T; Endo K; Shimizu Y Peripheral nerve regeneration across an 80-mm gap bridged by a polyglycolic acid (PGA)–collagen tube filled with laminin-coated collagen fibers: a histological and electrophysiological evaluation of regenerated nerves. *Brain Res.* 2000, 868 (2), 315–328. [PubMed: 10854584]
- (229). Farzamfar S; Esmailpour F; Rahmati M; Vaez A; Mirzaei M; Garmabi B; Shayannia A; Ebrahimi E; Vahedi H; Salehi M Poly-lactic acid/gelatin nanofiber (PLA/GTNF) conduits containing platelet-rich plasma for peripheral nerve regeneration. *International Journal of Health Studies* 2017, 3 (2). DOI: 10.22100/IJHS.V3I2.236
- (230). Bini T; Gao S; Xu X; Wang S; Ramakrishna S; Leong KW Peripheral nerve regeneration by microbraided poly (L-lactide-co-glycolide) biodegradable polymer fibers. *J. Biomed. Mater. Res* 2004, 68 (2), 286–295.
- (231). Luis AL; Rodrigues JM; Amado S; Veloso AP; Armada-Da-Silva PA; Raimondo S; Fregnan F; Ferreira AJ; Lopes MA; Santos JD; et al. PLGA 90/10 and caprolactone biodegradable nerve guides for the reconstruction of the rat sciatic nerve. *Microsurgery: Official Journal of the International Microsurgical Society and the European Federation of Societies for Microsurgery* 2007, 27 (2), 125–137.
- (232). Oh SH; Kim JH; Song KS; Jeon BH; Yoon JH; Seo TB; Namgung U; Lee IW; Lee JH Peripheral nerve regeneration within an asymmetrically porous PLGA/Pluronic F127 nerve guide conduit. *Biomaterials* 2008, 29 (11), 1601–1609. [PubMed: 18155135]
- (233). Li Y; Yu Z; Men Y; Chen X; Wang B Laminin-chitosan-PLGA conduit co-transplanted with Schwann and neural stem cells to repair the injured recurrent laryngeal nerve. *Exp. Ther. Med* 2018, 16 (2), 1250–1258. [PubMed: 30116376]

- (234). Peng S-W; Li C-W; Chiu M; Wang G-J Nerve guidance conduit with a hybrid structure of a PLGA microfibrinous bundle wrapped in a micro/nanostructured membrane. *Int. J. Nanomed* 2017, 12, 421.
- (235). Sundback CA; Shyu JY; Wang Y; Faquin WC; Langer RS; Vacanti JP; Hadlock TA Biocompatibility analysis of poly (glycerol sebacate) as a nerve guide material. *Biomaterials* 2005, 26 (27), 5454–5464. [PubMed: 15860202]
- (236). Vijayavenkataraman S; Kannan S; Cao T; Fuh JYH; Sriram G; Lu WF 3D-printed PCL/PPy conductive scaffolds as three-dimensional porous nerve guide conduits (ngcs) for peripheral nerve injury repair. *Front. Bioeng. Biotechnol* 2019, 7, 266. [PubMed: 31750293]
- (237). Frost HK; Andersson T; Johansson S; Englund-Johansson U; Ekström P; Dahlin LB; Johansson F Electrospun nerve guide conduits have the potential to bridge peripheral nerve injuries in vivo. *Sci. Rep* 2018, 8 (1), 1–13. [PubMed: 29311619]
- (238). Yu W; Zhao W; Zhu C; Zhang X; Ye D; Zhang W; Zhou Y; Jiang X; Zhang Z Sciatic nerve regeneration in rats by a promising electrospun collagen/poly (ϵ -caprolactone) nerve conduit with tailored degradation rate. *BMC Neurosci.* 2011, 12 (1), 1–14. [PubMed: 21208416]
- (239). Pinho AC; Fonseca AC; Serra AC; Santos JD; Coelho JF Peripheral nerve regeneration: current status and new strategies using polymeric materials. *Adv. Healthcare Mater* 2016, 5 (21), 2732–2744.
- (240). Lin C-C; Anseth KS PEG hydrogels for the controlled release of biomolecules in regenerative medicine. *Pharm. Res* 2009, 26 (3), 631–643. [PubMed: 19089601]
- (241). Wangenstein KJ; Kalliainen LK Collagen tube conduits in peripheral nerve repair: a retrospective analysis. *Hand* 2010, 5 (3), 273–277. [PubMed: 19937145]
- (242). Bozkurt A; Claeys KG; Schradling S; Rodler JV; Altinova H; Schulz JB; Weis J; Pallua N; van Neerven SG Clinical and biometrical 12-month follow-up in patients after reconstruction of the sural nerve biopsy defect by the collagen-based nerve guide Neuromaix. *Eur. J. Med.Res* 2017, 22 (1), 34. [PubMed: 28938917]
- (243). Du J; Chen H; Qing L; Yang X; Jia X Biomimetic neural scaffolds: a crucial step towards optimal peripheral nerve regeneration. *Biomater. Sci* 2018, 6 (6), 1299–1311. [PubMed: 29725688]
- (244). Park E-J; Kim E-S; Weber H-P; Wright RF; Mooney DJ Improved bone healing by angiogenic factor-enriched platelet-rich plasma and its synergistic enhancement by bone morphogenetic protein-2. *Int. J. Oral Maxillofac. Implants* 2008, 23 (5), 818. [PubMed: 19014150]
- (245). Sekiya N; Ichioka S; Terada D; Tsuchiya S; Kobayashi H Efficacy of a poly glycolic acid (PGA)/collagen composite nanofibre scaffold on cell migration and neovascularisation in vivo skin defect model. *Journal of plastic surgery and hand surgery* 2013, 47 (6), 498–502. [PubMed: 23596989]
- (246). Wernike E; Montjovent M-O; Liu Y; Wismeijer D; Hunziker EB; Siebenrock K-A; Hofstetter W; Klenke FM VEGF incorporated into calcium phosphate ceramics promotes vascularisation and bone formation in vivo. *Eur. Cell Mater* 2010, 19 (3), 30. [PubMed: 20178096]
- (247). Kampmann A; Lindhorst D; Schumann P; Zimmerer R; Kokemüller H; Rücker M; Gellrich N-C; Tavassol F Additive effect of mesenchymal stem cells and VEGF to vascularization of PLGA scaffolds. *Microvasc. Res* 2013, 90, 71–79. [PubMed: 23899416]
- (248). Kempen DH; Lu L; Heijink A; Hefferan TE; Creemers LB; Maran A; Yaszemski MJ; Dhert WJ Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. *Biomaterials* 2009, 30 (14), 2816–2825. [PubMed: 19232714]
- (249). Zhang Y; Yu T; Peng L; Sun Q; Wei Y; Han B Advancements in hydrogel-based drug sustained release systems for bone tissue engineering. *Front. Pharmacol* 2020, 11, 622. [PubMed: 32435200]
- (250). Van Hove AH; Burke K; Antonienko E; Brown III E; Benoit DS Enzymatically-responsive pro-angiogenic peptide-releasing poly (ethylene glycol) hydrogels promote vascularization in vivo. *J. Controlled Release* 2015, 217, 191–201.
- (251). Hoffman MD; Van Hove AH; Benoit DS Degradable hydrogels for spatiotemporal control of mesenchymal stem cells localized at decellularized bone allografts. *Acta Biomater.* 2014, 10 (8), 3431–3441. [PubMed: 24751534]

- (252). Van Hove AH; Beltejar M-JG; Benoit DS Development and in vitro assessment of enzymatically-responsive poly (ethylene glycol) hydrogels for the delivery of therapeutic peptides. *Biomaterials* 2014, 35 (36), 9719–9730. [PubMed: 25178558]
- (253). Van Hove AH; Antonienko E; Burke K; Brown E III; Benoit DS Temporally tunable, enzymatically responsive delivery of proangiogenic peptides from poly (ethylene glycol) hydrogels. *Adv. Healthcare Mater* 2015, 4 (13), 2002–2011.
- (254). Chato-Astrain J; Campos F; Roda O; Miralles E; Durand-Herrera D; Sáez-Moreno JA; García-García S; Alaminos M; Campos A; Carriel V In vivo evaluation of nanostructured fibrinagarose hydrogels with mesenchymal stem cells for peripheral nerve repair. *Front. Cell. Neurosci* 2018, 12, 501. [PubMed: 30627086]
- (255). Evangelista MS; Perez M; Salibian AA; Hassan JM; Darcy S; Paydar KZ; Wicker RB; Arcaute K; Mann BK; Evans GR Single-lumen and multi-lumen poly (ethylene glycol) nerve conduits fabricated by stereolithography for peripheral nerve regeneration in vivo. *J. Reconstr Microsurg* 2015, 31 (05), 327–335. [PubMed: 25893632]
- (256). Tao J; Zhang J; Du T; Xu X; Deng X; Chen S; Liu J; Chen Y; Liu X; Xiong M; et al. Rapid 3D printing of functional nanoparticle-enhanced conduits for effective nerve repair. *Acta Biomater.* 2019, 90, 49–59. [PubMed: 30930306]
- (257). Stevens MM; Marini RP; Schaefer D; Aronson J; Langer R; Shastri VP In vivo engineering of organs: the bone bioreactor. *Proc. Natl. Acad. Sci. U. S. A* 2005, 102 (32), 11450–11455. [PubMed: 16055556]
- (258). Hokugo A; Ozeki M; Kawakami O; Sugimoto K; Mushimoto K; Morita S; Tabata Y Augmented bone regeneration activity of platelet-rich plasma by biodegradable gelatin hydrogel. *Tissue Eng.* 2005, 11 (7–8), 1224–1233. [PubMed: 16144458]
- (259). Hokugo A; Sawada Y; Hokugo R; Iwamura H; Kobuchi M; Kambara T; Morita S; Tabata Y Controlled release of platelet growth factors enhances bone regeneration at rabbit calvaria. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology* 2007, 104 (1), 44–48.
- (260). Hoffman MD; Benoit DS Emulating native periosteum cell population and subsequent paracrine factor production to promote tissue engineered periosteum-mediated allograft healing. *Biomaterials* 2015, 52, 426–440. [PubMed: 25818449]
- (261). Baldwin J; Wagner F; Martine L; Holzapfel B; Theodoropoulos C; Bas O; Savi F; Werner C; De-Juan-Pardo E; Hutmacher D Periosteum tissue engineering in an orthotopic in vivo platform. *Biomaterials* 2017, 121, 193–204. [PubMed: 28092776]
- (262). Srouji S; Rachmiel A; Blumenfeld I; Livne E Mandibular defect repair by TGF- β and IGF-1 released from a biodegradable osteoconductive hydrogel. *J. Cranio Maxill Surg* 2005, 33 (2), 79–84.
- (263). Sivashanmugam A; Charoenlarp P; Deepthi S; Rajendran A; Nair SV; Iseki S; Jayakumar R Injectable shear-thinning CaSO₄/FGF-18-incorporated Chitin–PLGA hydrogel enhances bone regeneration in mice cranial bone defect model. *ACS Appl. Mater. Interfaces* 2017, 9 (49), 42639–42652. [PubMed: 29143524]
- (264). Madden LR; Mortisen DJ; Sussman EM; Dupras SK; Fugate JA; Cuy JL; Hauch KD; Laflamme MA; Murry CE; Ratner BD Proangiogenic scaffolds as functional templates for cardiac tissue engineering. *Proc. Natl. Acad. Sci U. S. A* 2010, 107 (34), 15211–15216. [PubMed: 20696917]
- (265). Oliviero O; Ventre M; Netti P Functional porous hydrogels to study angiogenesis under the effect of controlled release of vascular endothelial growth factor. *Acta Biomater.* 2012, 8 (9), 3294–3301. [PubMed: 22641106]
- (266). Vajda J; Milojevi M; Maver U; Vihar B Microvascular Tissue Engineering—A Review. *Biomedicines* 2021, 9 (6), 589. [PubMed: 34064101]
- (267). Evans G; Brandt K; Widmer M; Lu L; Meszlenyi R; Gupta P; Mikos A; Hodges J; Williams J; Gurlek A; et al. In vivo evaluation of poly (L-lactic acid) porous conduits for peripheral nerve regeneration. *Biomaterials* 1999, 20 (12), 1109–1115. [PubMed: 10382826]
- (268). Hsu S. h.; Chang WC; Yen CT Novel flexible nerve conduits made of water-based biodegradable polyurethane for peripheral nerve regeneration. *J. Biomed. Mater. Res., Part A* 2017, 105 (5), 1383–1392.

- (269). Niu Y; Chen KC; He T; Yu W; Huang S; Xu K Scaffolds from block polyurethanes based on poly (ϵ -caprolactone)(PCL) and poly (ethylene glycol)(PEG) for peripheral nerve regeneration. *Biomaterials* 2014, 35 (14), 4266–4277. [PubMed: 24582378]
- (270). Saberianpour S; Heidarzadeh M; Geranmayeh MH; Hosseinkhani H; Rahbarghazi R; Nouri M Tissue engineering strategies for the induction of angiogenesis using biomaterials. *J. Biol. Eng* 2018, 12 (1), 1–15. [PubMed: 29339972]
- (271). Rosso G; Young P; Shahin V Implications of Schwann cells biomechanics and mechanosensitivity for peripheral nervous system physiology and pathophysiology. *Front. Mol. Neurosci* 2017, 10, 345. [PubMed: 29118694]
- (272). Wu S; Xu R; Duan B; Jiang P Three-dimensional hyaluronic acid hydrogel-based models for in vitro human iPSC-derived NPC culture and differentiation. *J. Mater. Chem. B* 2017, 5 (21), 3870–3878. [PubMed: 28775848]
- (273). Lampe KJ; Antaris AL; Heilshorn SC Design of three-dimensional engineered protein hydrogels for tailored control of neurite growth. *Acta Biomater.* 2013, 9 (3), 5590–5599. [PubMed: 23128159]
- (274). Zuo Y Substrate Stress Relaxation Regulates Cell Migration; Johns Hopkins University, 2019.
- (275). Byfield FJ; Reen RK; Shentu T-P; Levitan I; Gooch KJ Endothelial actin and cell stiffness is modulated by substrate stiffness in 2D and 3D. *J. Biomech* 2009, 42 (8), 1114–1119. [PubMed: 19356760]
- (276). Mason BN; Starchenko A; Williams RM; Bonassar LJ; Reinhart-King CA Tuning three-dimensional collagen matrix stiffness independently of collagen concentration modulates endothelial cell behavior. *Acta Biomater.* 2013, 9 (1), 4635–4644. [PubMed: 22902816]
- (277). Trappmann B; Baker BM; Polacheck WJ; Choi CK; Burdick JA; Chen CS Matrix degradability controls multicellularity of 3D cell migration. *Nat. Commun* 2017, 8 (1), 1–8. [PubMed: 28232747]
- (278). Wang L; Wu S; Cao G; Fan Y; Dunne N; Li X Biomechanical studies on biomaterial degradation and co-cultured cells: mechanisms, potential applications, challenges and prospects. *J. Mater. Chem. B* 2019, 7 (47), 7439–7459. [PubMed: 31539007]
- (279). Shih YC Effects of degradation on mechanical properties of tissue-engineering poly (glycolic acid) scaffolds, Thesis, Yale University, 2015.
- (280). Li Y; Hoffman MD; Benoit DS Matrix metalloproteinase (MMP)-degradable tissue engineered periosteum coordinates allograft healing via early stage recruitment and support of host neurovasculature. *Biomaterials* 2021, 268, 120535. [PubMed: 33271450]
- (281). Du Y; Herath SC; Wang Q.-g.; Wang D.-a.; Asada HH; Chen PC Three-dimensional characterization of mechanical interactions between endothelial cells and extracellular matrix during angiogenic sprouting. *Sci. Rep* 2016, 6 (1), 1–14. [PubMed: 28442746]
- (282). Rundhaug JE Matrix metalloproteinases and angiogenesis. *J. Cell. Mol. Med* 2005, 9 (2), 267–285. [PubMed: 15963249]
- (283). Dinglasan LAV The Role of Matrix Metalloproteinases in Axon Guidance and Neurite Outgrowth, Thesis, Yale University, 2008.
- (284). Moons LK; Buyens T; Lemmens K; Salinas-Navarro M; Behrendt N; Van Hove I; Gaublomme D; De Groef L MMP-2 and MT1-MMP as axonal outgrowth-promoting molecules in the neuroretina. *Invest Ophth Vis Sci.* 2014, 55 (13), 3515–3515.
- (285). Man AJ; Davis HE; Itoh A; Leach JK; Bannerman P Neurite outgrowth in fibrin gels is regulated by substrate stiffness. *Tissue Eng., Part A* 2011, 17 (23–24), 2931–2942. [PubMed: 21882895]
- (286). Woodruff MA; Hutmacher DW The return of a forgotten polymer—Polycaprolactone in the 21st century. *Prog. Polym. Sci* 2010, 35 (10), 1217–1256.
- (287). Ivanovski S; Vaquette C; Gronthos S; Hutmacher DW; Bartold PM Multiphasic Scaffolds for Periodontal Tissue Engineering. *J. Dent. Res* 2014, 93 (12), 1212–1221. [PubMed: 25139362]
- (288). Mohammad JA; Warnke PH; Pan Y; Shenaq S Increased axonal regeneration through a biodegradable amniotic tube nerve conduit: effect of local delivery and incorporation of nerve growth factor/hyaluronic acid media. *Ann. Plast. Surg* 2000, 44 (1), 59–64. [PubMed: 10651367]

- (289). Rich KM; Alexander TD; Pryor JC; Hollowell JP Nerve growth factor enhances regeneration through silicone chambers. *Exp. Neurol* 1989, 105 (2), 162–170. [PubMed: 2753116]
- (290). Lee AC; Vivian MY; Lowe III JB; Brenner MJ; Hunter DA; Mackinnon SE; Sakiyama-Elbert SE Controlled release of nerve growth factor enhances sciatic nerve regeneration. *Exp. Neurol* 2003, 184 (1), 295–303. [PubMed: 14637100]
- (291). Lin Y-C; Ramadan M; Hronik-Tupaj M; Kaplan DL; Philips BJ; Sivak W; Rubin JP; Marra KG spatially controlled delivery of neurotrophic factors in silk fibroin-based nerve conduits for peripheral nerve repair. *Ann. Plast. Surg* 2011, 67 (2), 147–155. [PubMed: 21712696]
- (292). Wood MD; Kim H; Bilbily A; Kemp SW; Lafontaine C; Gordon T; Shoichet MS; Borschel GH GDNF released from microspheres enhances nerve regeneration after delayed repair. *Muscle Nerve* 2012, 46 (1), 122–124. [PubMed: 22692999]
- (293). Chen Z-Y; Chai Y-F; Cao L; Lu C-L; He C Glial cell line-derived neurotrophic factor enhances axonal regeneration following sciatic nerve transection in adult rats. *Brain Res.* 2001, 902 (2), 272–276. [PubMed: 11384621]
- (294). Sanghvi AB; Murray ABJL Tissue engineering of peripheral nerve. *Encyclopedia of biomaterials and biomedical engineering*; CRC Press, 2008; pp 2811–2819.
- (295). Terris DJ; Toft KM; Moir M; Lum J; Wang M Brain-derived neurotrophic factor-enriched collagen tubule as a substitute for autologous nerve grafts. *Arch. Otolaryngol., Head Neck Surg* 2001, 127 (3), 294–298. [PubMed: 11255474]
- (296). Hollinger JO; Hart CE; Hirsch SN; Lynch S; Friedlaender GE Recombinant human platelet-derived growth factor: biology and clinical applications. *JBJS* 2008, 90 (Supplement_1), 48–54.
- (297). Young S; Patel ZS; Kretlow JD; Murphy MB; Mountziaris PM; Baggett LS; Ueda H; Tabata Y; Jansen JA; Wong M; et al. Dose effect of dual delivery of vascular endothelial growth factor and bone morphogenetic protein-2 on bone regeneration in a rat critical-size defect model. *Tissue Eng., Part A* 2009, 15 (9), 2347–2362. [PubMed: 19249918]
- (298). Pu LL; Syed SA; Reid M; Patwa H; Goldstein JM; Forman DL; Thomson JG; et al. Effects of nerve growth factor on nerve regeneration through a vein graft across a gap. *Plast Reconstr Surg* 1999, 104 (5), 1379–1385. [PubMed: 10513921]
- (299). Zieris A; Prokoph S; Levental KR; Welzel PB; Grimmer M; Freudenberg U; Werner C FGF-2 and VEGF functionalization of starPEG-heparin hydrogels to modulate biomolecular and physical cues of angiogenesis. *Biomaterials* 2010, 31 (31), 7985–7994. [PubMed: 20674970]
- (300). Khorsand B; Nicholson N; Do A-V; Femino JE; Martin JA; Petersen E; Guetschow B; Fredericks DC; Salem AK Regeneration of bone using nanoplex delivery of FGF-2 and BMP-2 genes in diaphyseal long bone radial defects in a diabetic rabbit model. *J. Controlled Release* 2017, 248, 53–59.
- (301). Charles LF; Woodman JL; Ueno D; Gronowicz G; Hurley MM; Kuhn LT Effects of low dose FGF-2 and BMP-2 on healing of calvarial defects in old mice. *Exp. Gerontol* 2015, 64, 62–69. [PubMed: 25681640]
- (302). Mastrullo V; Cathery W; Velliou E; Madeddu P; Campagnolo P Angiogenesis in tissue engineering: as nature intended? *Front. Bioeng. Biotechnol* 2020, 8, 188. [PubMed: 32266227]
- (303). Kuttappan S; Mathew D; Jo J.-i.; Tanaka R; Menon D; Ishimoto T; Nakano T; Nair SV; Nair MB; Tabata Y Dual release of growth factor from nanocomposite fibrous scaffold promotes vascularisation and bone regeneration in rat critical sized calvarial defect. *Acta Biomater.* 2018, 78, 36–47. [PubMed: 30067947]
- (304). Sharon J; Puleo D Immobilization of glycoproteins, such as VEGF, on biodegradable substrates. *Acta Biomater.* 2008, 4 (4), 1016–1023. [PubMed: 18359670]
- (305). Budiraharjo R; Neoh KG; Kang E-T Enhancing bioactivity of chitosan film for osteogenesis and wound healing by covalent immobilization of BMP-2 or FGF-2. *J. Biomater. Sci., Polym. Ed* 2013, 24 (6), 645–662. [PubMed: 23565907]
- (306). Shekaran A; García JR; Clark AY; Kavanaugh TE; Lin AS; Guldberg RE; García AJ Bone regeneration using an alpha 2 beta 1 integrin-specific hydrogel as a BMP-2 delivery vehicle. *Biomaterials* 2014, 35 (21), 5453–5461. [PubMed: 24726536]
- (307). Sacchi V; Mittermayr R; Hartinger J; Martino MM; Lorentz KM; Wolbank S; Hofmann A; Largo RA; Marschall JS; Groppa E; et al. Long-lasting fibrin matrices ensure stable and

- functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164. *Proc. Natl. Acad. Sci. U. S. A* 2014, 111 (19), 6952–6957. [PubMed: 24778233]
- (308). Vardar E; Larsson HM; Allazetta S; Engelhardt EM; Pinnagoda K; Vythilingam G; Hubbell JA; Lutolf MP; Frey P Microfluidic production of bioactive fibrin micro-beads embedded in crosslinked collagen used as an injectable bulking agent for urinary incontinence treatment. *Acta Biomater.* 2018, 67, 156–166. [PubMed: 29197579]
- (309). Jha AK; Mathur A; Svedlund FL; Ye J; Yeghiazarians Y; Healy KE Molecular weight and concentration of heparin in hyaluronic acid-based matrices modulates growth factor retention kinetics and stem cell fate. *J. Controlled Release* 2015, 209, 308–316.
- (310). Martino MM; Briquez PS; Ranga A; Lutolf MP; Hubbell JA Heparin-binding domain of fibrin (ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. *Proc. Natl. Acad. Sci. U. S. A* 2013, 110 (12), 4563–4568. [PubMed: 23487783]
- (311). Martino MM; Briquez PS; Güç E; Tortelli F; Kilarski WW; Metzger S; Rice JJ; Kuhn GA; Müller R; Swartz MA; et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. *Science* 2014, 343 (6173), 885–888. [PubMed: 24558160]
- (312). Comoglio PM; Boccaccio C; Trusolino L Interactions between growth factor receptors and adhesion molecules: breaking the rules. *Curr. Opin. Cell Biol* 2003, 15 (5), 565–571. [PubMed: 14519391]
- (313). Salmerón-Sánchez M; Dalby MJ Synergistic growth factor microenvironments. *Chem. Commun* 2016, 52 (91), 13327–13336.
- (314). Subbiah R; Guldberg RE Materials science and design principles of growth factor delivery systems in tissue engineering and regenerative medicine. *Adv. Healthcare Mater* 2019, 8 (1), 1801000.
- (315). Itoh S; Suzuki M; Yamaguchi I; Takakuda K; Kobayashi H; Shinomiya K; Tanaka J Development of a nerve scaffold using a tendon chitosan tube. *Artif. Organs* 2003, 27 (12), 1079–1088. [PubMed: 14678421]
- (316). Itoh S; Matsuda A; Kobayashi H; Ichinose S; Shinomiya K; Tanaka J Effects of a laminin peptide (YIGSR) immobilized on crab-tendon chitosan tubes on nerve regeneration. *J. Biomed. Mater. Res., Part B* 2005, 73 (2), 375–382.
- (317). Sedaghati T; Jell G; Seifalian A Investigation of Schwann cell behaviour on RGD-functionalised bioabsorbable nanocomposite for peripheral nerve regeneration. *New Biotechnol.* 2014, 31 (3), 203–213.
- (318). Zhu L; Wang K; Ma T; Huang L; Xia B; Zhu S; Yang Y; Liu Z; Quan X; Luo K; et al. Noncovalent bonding of RGD and YIGSR to an electrospun poly (ϵ -caprolactone) conduit through peptide self-assembly to synergistically promote sciatic nerve regeneration in rats. *Adv. Healthcare Mater* 2017, 6 (8), 1600860.
- (319). Taite LJ; Yang P; Jun HW; West JL Nitric oxide-releasing polyurethane–PEG copolymer containing the YIGSR peptide promotes endothelialization with decreased platelet adhesion. *J. Biomed. Mater. Res., Part B* 2008, 84 (1), 108–116.
- (320). Kibbey MC; Kleinman HK; Corcoran ML; Wahl LM Laminin SIKVAV peptide-induced angiogenesis in vivo is potentiated by neutrophils. *J. Cell. Physiol* 1994, 160 (1), 185–193. [PubMed: 7517404]
- (321). Li C; Hill A; Imran M In vitro and in vivo studies of ePTFE vascular grafts treated with P15 peptide. *J. Biomater. Sci., Polym. Ed* 2005, 16 (7), 875–891. [PubMed: 16128294]
- (322). Fittkau M; Zilla P; Bezuidenhout D; Lutolf M; Human P; Hubbell JA; Davies N The selective modulation of endothelial cell mobility on RGD peptide containing surfaces by YIGSR peptides. *Biomaterials* 2005, 26 (2), 167–174. [PubMed: 15207463]
- (323). Massia SP; Hubbell JA Vascular endothelial cell adhesion and spreading promoted by the peptide REDV of the IIICS region of plasma fibronectin is mediated by integrin alpha 4 beta 1. *J. Biol. Chem* 1992, 267 (20), 14019–14026. [PubMed: 1629200]
- (324). Hamada Y; Yuki K; Okazaki M; Fujitani W; Matsumoto T; Hashida MK; Harutsugu K; Nokihara K; Daito M; Matsuura N; et al. Osteopontin-derived peptide SVVYGLR induces angiogenesis in vivo. *Dent. Mater. J* 2004, 23 (4), 650–655. [PubMed: 15688734]

- (325). Adini A; Adini I; Chi Z.-I.; Derda R; Birsner AE; Matthews BD; D'Amato RJ A novel strategy to enhance angiogenesis in vivo using the small VEGF-binding peptide PR1P. *Angiogenesis* 2017, 20 (3), 399–408. [PubMed: 28397127]
- (326). Miller JS; Stevens KR; Yang MT; Baker BM; Nguyen D-HT; Cohen DM; Toro E; Chen AA; Galie PA; Yu X; et al. Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. *Nat. Mater* 2012, 11 (9), 768–774. [PubMed: 22751181]
- (327). Li S; Xiong Z; Wang X; Yan Y; Liu H; Zhang R Direct fabrication of a hybrid cell/hydrogel construct by a double-nozzle assembling technology. *J. Bioact. Compat. Polym* 2009, 24 (3), 249–265.
- (328). Lee S-J; Nowicki M; Harris B; Zhang LG Fabrication of a highly aligned neural scaffold via a table top stereolithography 3D printing and electrospinning. *Tissue Eng., Part A* 2017, 23 (11–12), 491–502. [PubMed: 27998214]
- (329). Grasman JM; Ferreira JA; Kaplan DL Tissue Models for Neurogenesis and Repair in 3D. *Adv. Funct. Mater* 2018, 28 (48), 1803822. [PubMed: 32440261]
- (330). Jafarkhani M; Salehi Z; Aidun A; Shokrgozar MA Bioprinting in Vascularization Strategies. *Iran. Biomed. J* 2019, 23 (1), 9. [PubMed: 30458600]
- (331). Moreno Madrid AP; Vrech SM; Sanchez MA; Rodriguez AP Advances in additive manufacturing for bone tissue engineering scaffolds. *Mater. Sci. Eng., C* 2019, 100, 631.
- (332). Lee VK; Kim DY; Ngo H; Lee Y; Seo L; Yoo S-S; Vincent PA; Dai G Creating perfused functional vascular channels using 3D bio-printing technology. *Biomaterials* 2014, 35 (28), 8092–8102. [PubMed: 24965886]
- (333). Hsiao D; Hsu S-H; Chen R-S; Chen M-H Characterization of designed directional polylactic acid 3D scaffolds for neural differentiation of human dental pulp stem cells. *J. Formosan Med. Assoc* 2020, 119 (1), 268–275. [PubMed: 31155229]
- (334). Kang H-W; Lee SJ; Ko IK; Kengla C; Yoo JJ; Atala A A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. *Nat. Biotechnol* 2016, 34 (3), 312–319. [PubMed: 26878319]
- (335). Jain RK; Au P; Tam J; Duda DG; Fukumura D Engineering vascularized tissue. *Nat. Biotechnol* 2005, 23 (7), 821–823. [PubMed: 16003365]
- (336). Asa'ad F; Pagni G; Pilipchuk SP; Gianni AB; Giannobile WV; Rasperini G 3D-Printed Scaffolds and Biomaterials: Review of Alveolar Bone Augmentation and Periodontal Regeneration Applications. *Int. J. Dent* 2016, 2016, 1239842. [PubMed: 27366149]
- (337). Charbonneau AM; Kinsella JM; Tran SD 3D Cultures of Salivary Gland Cells in Native or Gelled Egg Yolk Plasma, Combined with Egg White and 3D-Printing of Gelled Egg Yolk Plasma. *Materials* 2019, 12 (21), 3480.
- (338). Ferreira JN; Rungarunlert S; Urkasemsin G; Adine C; Souza GR Three-Dimensional Bioprinting Nanotechnologies towards Clinical Application of Stem Cells and Their Secretome in Salivary Gland Regeneration. *Stem Cells Int.* 2016, 2016, 7564689. [PubMed: 28090208]
- (339). Chansaenroj A; Yodmuang S; Ferreira JN Trends in Salivary Gland Tissue Engineering: From Stem Cells to Secretome and Organoid Bioprinting. *Tissue Eng., Part B* 2021, 27 (2), 155–165.
- (340). Barrows CML; Wu D; Farach-Carson MC; Young S Building a Functional Salivary Gland for Cell-Based Therapy: More than Secretory Epithelial Acini. *Tissue Eng., Part A* 2020, 26 (23–24), 1332–1348. [PubMed: 32829674]
- (341). Bae H; Puranik AS; Gauvin R; Edalat F; Carrillo-Conde B; Peppas NA; Khademhosseini A Building vascular networks. *Sci. Transl. Med* 2012, 4 (160), 160ps23–160ps23.
- (342). Davis GE; Stratman AN; Sacharidou A; Koh W Molecular basis for endothelial lumen formation and tubulogenesis during vasculogenesis and angiogenic sprouting. *International review of cell and molecular biology*; Elsevier, 2011; Vol. 288, pp 101–165. [PubMed: 21482411]
- (343). Chan ZC-K; Oentaryo MJ; Lee CW MMP-mediated modulation of ECM environment during axonal growth and NMJ development. *Neurosci. Lett* 2020, 724, 134822. [PubMed: 32061716]
- (344). Elisseff J; Puleo C; Yang F; Sharma B Advances in skeletal tissue engineering with hydrogels. *Orthodontics & craniofacial research* 2005, 8 (3), 150–161. [PubMed: 16022717]

- (345). Gunn JW; Turner SD; Mann BK Adhesive and mechanical properties of hydrogels influence neurite extension. *J. Biomed. Mater. Res* 2005, 72 (1), 91–97.
- (346). Lutolf M; Hubbell J Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. *Nat. Biotechnol* 2005, 23 (1), 47–55. [PubMed: 15637621]
- (347). Culver JC; Hoffmann JC; Poché RA; Slater JH; West JL ; Dickinson ME Three-dimensional biomimetic patterning in hydrogels to guide cellular organization. *Adv. Mater* 2012, 24 (17), 2344–2348. [PubMed: 22467256]
- (348). Klotz BJ; Gawlitta D; Rosenberg AJ; Malda J; Melchels FP Gelatin-methacryloyl hydrogels: towards biofabrication-based tissue repair. *Trends Biotechnol.* 2016, 34 (5), 394–407. [PubMed: 26867787]
- (349). Moore AN; Silva TLL; Carrejo NC; Marmolejo CAO; Li I-C; Hartgerink JD Nanofibrous peptide hydrogel elicits angiogenesis and neurogenesis without drugs, proteins, or cells. *Biomaterials* 2018, 161, 154–163. [PubMed: 29421552]
- (350). Moshayedi P; Nih LR; Llorente IL; Berg AR; Cinkornpumin J; Lowry WE; Segura T; Carmichael ST Systematic optimization of an engineered hydrogel allows for selective control of human neural stem cell survival and differentiation after transplantation in the stroke brain. *Biomaterials* 2016, 105, 145–155. [PubMed: 27521617]
- (351). Shubin AD; Felong TJ; Schutrum BE; Joe DSL; Ovitt CE; Benoit DSW Encapsulation of primary salivary gland cells in enzymatically degradable poly(ethylene glycol) hydrogels promotes acinar cell characteristics. *Acta Biomater.* 2017, 50, 437–449. [PubMed: 28039063]
- (352). Song Y; Uchida H; Sharipol A; Piraino L; Mereness JA; Ingalls MH; Rebhahn J; Newlands SD; DeLouise LA; Ovitt CE; Benoit DSW Development of a functional salivary gland tissue chip with potential for high-content drug screening. *Communications Biology* 2021, 4 (1), 361. [PubMed: 33742114]
- (353). Luginbuehl V; Meinel L; Merkle HP; Gander B Localized delivery of growth factors for bone repair. *Eur. J. Pharm. Biopharm* 2004, 58 (2), 197–208. [PubMed: 15296949]
- (354). Sahoo S; Ang LT; Goh JCH; Toh SL Growth factor delivery through electrospun nanofibers in scaffolds for tissue engineering applications. *J. Biomed. Mater. Res., Part A* 2009, 93 (4), 1539–1550.
- (355). Farokhi M; Mottaghitlab F; Shokrgozar MA; Ai J; Hadjati J; Azami M Bio-hybrid silk fibroin/calcium phosphate/PLGA nanocomposite scaffold to control the delivery of vascular endothelial growth factor. *Mater. Sci Eng., C* 2014, 35, 401–410.
- (356). Wei G; Jin Q; Giannobile WV; Ma PX Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. *J. Controlled Release* 2006, 112 (1), 103–110.
- (357). Whitehead TJ; Avila COC; Sundararaghavan HG Combining growth factor releasing microspheres within aligned nanofibers enhances neurite outgrowth. *J. Biomed. Mater. Res., Part A* 2018, 106 (1), 17–25.
- (358). Grozdanic SD; Lazic T; Kuehn MH; Harper MM; Kardon RH; Kwon YH; Lavik EB; Sakaguchi DS Exogenous modulation of intrinsic optic nerve neuroprotective activity. *Graefe's Arch. Clin. Exp. Ophthalmol* 2010, 248 (8), 1105–1116. [PubMed: 20229104]
- (359). Kempen DH; Lu L; Hefferan TE; Creemers LB; Maran A; Classic KL; Dhert WJ; Yaszemski MJ Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. *Biomaterials* 2008, 29 (22), 3245–3252. [PubMed: 18472153]
- (360). Chiono V; Tonda-Turo C Trends in the design of nerve guidance channels in peripheral nerve tissue engineering. *Prog. Neurobiol* 2015, 131, 87–104. [PubMed: 26093353]
- (361). Vo TN; Kasper FK; Mikos AG Strategies for controlled delivery of growth factors and cells for bone regeneration. *Adv. Drug Delivery Rev* 2012, 64 (12), 1292–1309.
- (362). Santos MI; Reis RL Vascularization in bone tissue engineering: physiology, current strategies, major hurdles and future challenges. *Macromol Biosci.* 2010, 10 (1), 12–27. [PubMed: 19688722]
- (363). Baldwin J; Antille M; Bonda U; De-Juan-Pardo EM; Khosrotehrani K; Ivanovski S; Petcu EB; Huttmacher DW In vitro pre-vascularisation of tissue-engineered constructs A co-culture perspective. *Vasc. Cell* 2014, 6 (1), 1–16. [PubMed: 24472220]

- (364). Mercado-Pagán ÁE; Stahl AM; Shanjani Y; Yang Y Vascularization in bone tissue engineering constructs. *Ann. Biomed. Eng* 2015, 43 (3), 718–729. [PubMed: 25616591]
- (365). Doss MX; Sachinidis A Current challenges of iPSC-based disease modeling and therapeutic implications. *Cells* 2019, 8 (5), 403.
- (366). Rothe R; Hauser S; Neuber C; Laube M; Schulze S; Rammelt S; Pietzsch J Adjuvant drug-assisted bone healing: Advances and challenges in drug delivery approaches. *Pharmaceutics* 2020, 12 (5), 428.
- (367). Herten M; Jung RE; Ferrari D; Rothamel D; Golubovic V; Molenberg A; Hammerle CH; Becker J; Schwarz F Biodegradation of different synthetic hydrogels made of polyethylene glycol hydrogel/RGD-peptide modifications: an immunohistochemical study in rats. *Clin Oral Implants Res.* 2009, 20 (2), 116–25. [PubMed: 19077154]
- (368). Mammadov R; Mammadov B; Toksoz S; Aydin B; Yagci R; Tekinay AB; Guler MO Heparin mimetic peptide nanofibers promote angiogenesis. *Biomacromolecules* 2011, 12 (10), 3508–19. [PubMed: 21853983]
- (369). Miller JS; Shen CJ; Legant WR; Baranski JD; Blakely BL; Chen CS Bioactive hydrogels made from step-growth derived PEG-peptide macromers. *Biomaterials* 2010, 31 (13), 3736–43. [PubMed: 20138664]
- (370). Marrella A; Lee TY; Lee DH; Karuthedom S; Syla D; Chawla A; Khademhosseini A; Jang HL Engineering vascularized and innervated bone biomaterials for improved skeletal tissue regeneration. *Mater. Today (Oxford, U. K.)* 2018, 21 (4), 362–376.




Figure 1. Depiction of Wallerian degeneration [Reproduced with permission from ref 21. Copyright 2017 IntechOpen].




Figure 2. Angiogenesis is a tightly controlled process involving numerous cells and factors. (A) Ischemic tissue increases production of hypoxia inducible factor 1 α (HIF-1 α), which induces production of vascular endothelial growth factor (VEGF) that (B) signals to pericytes (green) and endothelial cells (ECs, blue), resulting in detachment of pericytes and sprouting of endothelial tip cells toward the VEGF gradient. (C) Tip cells (blue) then migrate, degrade the matrix, and (D) enable stalk cells (blue) to proliferate and form vessels via alignment into tube-like luminal structures, followed by (E) pericyte recruitment and (F) further remodeling and maturation. HIF-1 α , hypoxia inducible factor 1 α ; VEGF, vascular endothelial growth factor; Ang2, angiopoietin 2; PDGF, platelet derived growth factor; MMPs, matrix metalloproteinases; PLGF, placenta growth factor; SDF-1, stromal cell-derived factor 1; FGF, fibroblast growth factor; Ang1, angiopoietin 1 [Reproduced with permission from ref 32. Copyright 2015 Frontiers].




Figure 3. Anatomy of vascularized and innervated craniofacial tissues (A) cranial bone, (B) (i) mandibular bone (ii) and tooth, and (C) salivary glands. Part C was created with [BioRender.com](https://www.biorender.com/), agreement number: MB22XPLPSX.




Figure 4. (A) Longitudinal tracking of cranial bone defect healing in Col2.3GFP transgenic mice over a 6-week period illustrates osteogenesis and angiogenesis. Vessel, red; osteoblasts, green [Reproduced with permission from ref 57. Copyright 2018 Springer eBook]. (B) Reinnervation during cranial bone defect repair: representative whole-mount tile scans (left) and high-magnification images (right) of TUBB3 (beta III tubulin)-stained cranial defects (b–e) from days 3 to 28 postinjury compared to uninjured controls (a); TUBB3+ nerve fibers appear green; dashed white circles indicates margins of defect; white asterisks indicate midline suture and white scale bar, 200 mm [Reproduced with permission from ref 60. Copyright 2020 Elsevier].




Figure 5.

(A) Representative confocal images of costained of CD31 (blood vessels, red) and β 3-tubulin (nerves, green) on the cross sections of autografts, allografts, allografts modified by hydrolytically or MMP degradable tissue engineered periosteum (Hydro-TEP, MMP-TEP) at levels proximal (1), medial (2), and distal (3) in relation to the femoral head (scale bar = 20 μ m) at 3-week postsurgery. (B) Blood vessel density-dependent effects on nerve density, where regression analysis demonstrates a linear relationship ($R^2 = 0.74$) between revascularization and reinnervation, indicating their synergistic coordination during bone defect healing [Reproduced with permission from ref 280. Copyright 2021 Elsevier].




Figure 6.

(A) *In vivo* release profiles of (i) VEGF and (ii) BMP-2 were obtained after implantation of scaffold into the subcutaneous tissue mice for 28 days,³⁰³ where CSB and CSV represent nanocomposite fibrous scaffold (CS) loaded with BMP2 (B) and VEGF (V), respectively [Reproduced with permission from ref 303. Copyright 2018 Elsevier]. (B) Release kinetics of PLGA microspheres steady release of neurotrophic growth factors was detected for at least 60 days (i, BDNF) and 80 days (ii, GDNF) [Reproduced with the permission from ref 358. Copyright 2010 Springer Nature]. (C) Normalized *in vivo* release profile of BMP-2 from the four different implants in a rat subcutaneous implantation model, where Mps = PLGA microparticles loaded with BMP-2, and PPF = poly(propylene fumarate) [Reproduced with the permission from ref 359. Copyright 2008 Elsevier]. (D) Cumulative release of VEGF from the biohybrid scaffold with PLGA nanofibers, which displays a sustained release of VEGF over 28 days [Reproduced with the permission from ref 355. Copyright 2014 Elsevier].